Atherosclerosis

Vascular effects of insulin
pp. 1-1(1)
Author: Yki-Jarvinen H.

Plasminogen activator inhibitor type 1: Influence of metabolic factors and pharmacological control
pp. 1-1(1)
Authors: Tremoli E.; Banfi C.; Sironi L.; Mussoni L.

The atherogenic dyslipidemia of visceral obesity
pp. 1-1(1)
Author: Despres J.P.

Postprandial hyperglycemia is a risk factor for cardiovascular death in newly diagnosed type 2 diabetes: The Diabetes Intervention Study (DIS)
pp. 1-2(2)
Authors: Hanefeld M.; Julius U.; Schmechel H.; Schwanebeck U.

Chylomicron remnant kinetics in post-menopausal women with and without diabetes
pp. 2-2(1)
Authors: Barrett P.H.R.; Chan D.; Dane-Stewart C.; Stuckey B.; Mamo J.C.L.; Redgrave T.G.; Watts G.F.

Plasma cholesteryl ester transfer and hepatic lipase activity are determinants of low high density lipoprotein cholesterol associated with insulin resistance in type 2 Diabetic and non-diabetic subjects
pp. 2-2(1)
Authors: Van Tol A.; Riemens S.C.; Scheek L.M.; Dullaart R.P.F.

Thrombosis and fibrinolysis: Lessons from clinical trials
pp. 2-2(1)
Author: Meade T.W.

Functional mutations predisposing to arterial thrombosis
pp. 2-2(1)
Author: Kluft C.

The endogenous fibrinolytic enzyme system: Regulation and significance for cardiovascular disease
pp. 2-3(2)
Author: Hamsten A.

Tissue factor in atherothrombosis and the acute coronary syndromes
pp. 3-3(1)
Author: Badimon L.

Modulation of monocyte atherosclerotic and thrombotic antigen expression by platelets
pp. 3-3(1)
Authors: Lamb D.J.; Wright J.; Kharodia S.; Sandhu H.; Goodall A.H.

DNA-protein interactions at the t-PA promotor shear stress responsive element in intact human conduit vessels exposed to high shear stress
pp. 3-3(1)
Authors: Sjogren L.S.; Rasmussen L.; Hagg U.; Gan L.-M.; Jern S.

A new mechanism for platelet formation
pp. 3-3(1)
Authors: Pedreno J.; Moncusi M.; Cabre A.; Masana L.

Quantitative angiography and intravascular ultrasound as research tools for the imaging of atherosclerosis
pp. 4-4(1)
Author: de Feyter P.J.

Extravascular ultrasound and CT measures of coronary calcium as research tools to better understand early atherosclerosis/subclinical disease
pp. 4-4(1)
Author: Burke G.

Low dose metoprolol and fluvastatin slow progression of atherosclerosis: Main results from BCAPS
pp. 4-4(1)
Authors: Berglund G.; Wikstrand J.; Janzon L.; Wedel H.; Hedblad B.; BCAP study group

Coronary calcification score and predicted risk of coronary heart disease
pp. 4-4(1)
Authors: Thompson G.R.; Elkeles R.S.; Gibson K.; Rubens M.; Underwood R.

Noninvasive imaging and quantitation of atherosclerosis with radiolabeled oxidation-specific antibodies
pp. 4-5(2)
Authors: Tsimikas S.; Palinski W.; Shaw P.X.; Witztum J.L.

Are small lesions in atherosclerotic rabbit aorta shown by histology visible on magnetic resonance images?
pp. 5-5(1)
Authors: Hegyi L.; Hockings P.D.; Skepper J.N.; Carpenter T.A.; Whelan G.A.; Grimsditch D.C.; Benson G.M.; Suckling K.E.; Weissberg P.L.

Consistence between infection and atherosclerosis
pp. 5-5(1)
Author: Saikku P.

Infections and athero-thrombotic risk: The role of sero-epidemiology
pp. 5-5(1)
Author: Siscovick D.

Identifying and treating patients in the framework of infection and atherosclerosis
pp. 5-5(1)
Author: Gurfinkel E.P.

Folate deficiency, hyperhomocyst(e)inemia and Chlamydia pneumoniae: Who came first?
pp. 5-5(1)
Authors: Stanger O.; Tiran B.; Semmelrock H.; Rigler B.; Tiran A.

Leucocytes count and fibrinogen level are associated with carotid and femoral intima-media thickness
pp. 5-6(2)
Authors: Temelkova-Kurktschiev T.; Henkel E.; Fischer S.; Schaper F.; Hanefeld M.

Antibodies to Chlamydia pneumoniae react non-specifically with lipid on macrophages in human atherosclerotic arteries
pp. 6-6(1)
Authors: Sriskandarajah S.; Singh N.; Poston R.N.

Antibodies to Chlamydia pneumoniae are related to the intima-media thickness in the carotid artery and to an atherogenetic fatty acid profile
pp. 6-6(1)
Authors: Holmlund A.; Wessby B.; Gnarpe J.; Gnarpe H.; Kahan T.; Lind L.

Regulation of signal transduction in endothelial cells
pp. 6-6(1)
Author: Claesson-Welsh L.

Chemokines, monocytes, T cells, and the adaptive immune response in atherosclerosis
pp. 6-6(1)
Authors: Gu L.; Tseng S.; Libby P.; Rollins B.J.

Role of shear and pressure in regulation of PDGF-B in intact human conduit vessels
pp. 6-7(2)
Authors: Gan L.; Miocic M.; Johansson A.; Hagg U.; Doroudi R.; Jern S.

Elimiation of PDGF-B from only the circulating cells of APOE -/- mice significantly impacts atherosclerotic lesion formation
pp. 7-7(1)
Authors: Raines E.W.; Kozaki K.; Tang J.; Kaminski W.E.; Lindahl P.; Martin P.; Ross R.; Betsholtz C.

Proto-oncogene product Crk differentially interacts with PDGF- and -receptors
pp. 7-7(1)
Authors: Yokote K.; Mori S.; Matsumoto T.; Takemoto M.; Saito Y.

Cytokine regulation of endothelial cell function: New molecules in an old paradigm
pp. 7-7(1)
Authors: Mantovani A.; Garlanda C.

Statins and atherogenic process
pp. 7-8(2)
Authors: Davignon J.; Laaksonen R.

Statins and C-reactive protein (CRP)
pp. 8-8(1)
Author: Strandberg T.E.

Effect of statins on the synthesis of lipoprotein containing apo B-100
pp. 8-8(1)
Author: Catapano A.L.

Atorvastatin increases the catabolism of chylomicron remnants in normolipidemic subjects
pp. 8-8(1)
Authors: Parhofer K.G.; Barrett P.H.R.; Schwandt P.

Pravastatin reduces mortality: The Prospective Pravastatin Pooling Project
pp. 8-8(1)
Authors: Simes J.; Tonkin A.; Braunwald E.; Shepherd J.; Craven T.; Davis B.R.; Furberg C.

A large, 36 week study of the HDL-C raising effects and safety of simvastatin versus atorvastatin
pp. 8-9(2)
Authors: Crouse J.R.; Kastelein J.; Isaacsohn J.; Corsetti L.; Liu M.; Melino M.; Mercuri L.M.; Grady O.; Ose L.

Cholesterol-lowering therapy with pravastatin in older patients (aged 65 to 75) in the lipid study
pp. 9-9(1)
Authors: Hunt D.; Young P.; Simes J.; Colquhoun D.; Hague W.; Tonkin A.

Genetic interaction between hypertension and atherosclerosis in mice
pp. 10-10(1)
Authors: Knowles J.; Hodgin J.; Maeda N.

Transgenic mouse models of atherosclerosis and restenosis
pp. 10-10(1)
Author: Grass D.S.

The rabbit as a model for atherosclerosis and restenosis
pp. 10-10(1)
Authors: Campbell J.H.; Campbell G.R.

Bone marrow transplantation studies in mice to determine the role of macrophage-derived apolipoprotein E and the macrophage LDL receptor in diet-induced atherosclerosis
pp. 10-10(1)
Authors: Van Eck M.; Herijgers N.; Groot P.H.E.; Van Berkel T.J.C.

Dissociation between the evolution of VLDL apo B and HDL apo A-I metabolism on insulin therapy in non insulindependent diabetes mellitus (NIDDM) patients
pp. 11-11(1)
Authors: Duvillard L.; Verges B.; Pont F.; Florentin E.; Gambert P.

Insulin therapy partially corrects the defect of LDL receptor expression in non-insulin-dependent diabetes mellitus (NIDDM) patients: Quantification by flow cytometry
pp. 11-11(1)
Authors: Duvillard L.; Lizard G.; Verges B.; Florentin E.; Gambert P.

Increased expression of LOX-1 in diabetic rat arteries
pp. 11-11(1)
Authors: Chen M.; Sawamura T.; Masaki T.

Enhanced expression of osteopontin by high glucose: Involvement of osteopontin in diabetic vascular diseases
pp. 11-11(1)
Authors: Takemoto M.; Mori S.; Yokote K.; Asaumi S.; Saito Y.

Nitric oxide and cutaneous vasomotor response in coronary artery disease patients
pp. 11-12(2)
Authors: Tretjakovs P.; Kalnins U.; Dabina I.; Dinne I.; Erglis A.; Jurka A.

Low high density lipoprotein (HDL) and impaired glucose tolerance: Insights from stable isotope studies
pp. 12-12(1)
Authors: Pietzsch J.; Julius U.; Hanefeld M.

Association of LDL size and coronary risk factors in postmenopausal women
pp. 12-12(1)
Authors: Posadas-Romero C.; Zamora-Gonzalez J.; Cruz M.-G.; Hernandez-Ono A.; Cardoso-Saldana G.; Posadas-Sanchez R.

Impact of glycation on lipoproteins-induced generation of fibrinolytic regulators from vascular endothelial cells
pp. 12-12(1)
Authors: Shen G.; Ren S.; Zhang J.

The effect of beta-carotene and alpha-tocopherol supplementation on accelerated atherosclerosis in diabetic apoE deficient mice
pp. 12-12(1)
Authors: Keren P.; Shaish A.; George J.; Harats D.

Remnant lipoprotein cholesterol levels are higher in Type 2 diabetic subjects with macrovascular complications
pp. 13-13(1)
Authors: Devaraj S.; Hirany S.; Jialal I.

Angiographic severity and extent of coronary artery disease in type 1 diabetes
pp. 13-13(1)
Authors: Pajunen P.; Taskinen M.-R.; Nieminen M.S.; Syvanne M.

Apo E2 is associated with severe coronary artery disease in type 2 patients but is protective against severe disease in non-diabetic patients
pp. 13-13(1)
Authors: James R.W.; Kalix B.; Brulhart-Meynet M.-C.

Effects of atorvastatin vs. fenofibrate on lipoproteins, LDL-subfraction distribution and hemorheology in type 2 diabetic patients with mixed hyperlipoproteinemia
pp. 13-13(1)
Authors: Frost R.J.A.; Otto C.; Geiss H.C.; Parhofer K.; Schwandt P.

Insulin enhances platelet activation and aggregation in vitro
pp. 13-13(1)
Authors: Yngen M.; Li N.; Wallen N.H.; Hjemdahl P.

Apo E phenotype is associated with coronary artery calcification in the general population but not in type 1 diabetic patients
pp. 14-14(1)
Authors: Colhoun H.M.; Taskinen M.R.; Rubens M.B.; Fuller J.H.

Glycaemic control and plasma lipoproteins in menopausal women with type 2 diabetes treated with oral and transdermal combined hormone replacement therapy
pp. 14-14(1)
Authors: Darko D.A.; Dornhorst A.; O'Shea D.B.; Seed M.

Cholesteryl ester transfer is associated with HDL size and coronary artery calcification in type 1 diabetic and non-diabetic subjects
pp. 14-14(1)
Authors: Colhoun H.M.; Scheek L.M.; Otvos J.; Fuller J.H.; Van Tol A.

Low paraoxonase in small dense HDL may predispose to coronary heart disease in type 1 diabetes
pp. 14-14(1)
Authors: Valabhji J.; McColl A.J.; Dhanjil S.; Schachter M.; Richmond W.; Elkeles R.S.

HDL oxidability in type 2 diabetic patients
pp. 14-15(2)
Authors: Schreier L.; Sanguinetti S.; Verona J.; Elbert A.; Wikinski R.

Homocysteine augments impaired endothelium-dependent relaxation and cGMP formation in aortae of diabetic rats
pp. 15-15(1)
Authors: Jeremy J.Y.; Shukla N.; Marshman N.; Angelini G.D.; Taberner P.

Prevalence of impaired glucose tolerance in selected FCH patients
pp. 15-15(1)
Authors: Nativio V.; Cicero A.F.G.; Galetti C.; Reggiani A.; Favali D.; Gaddi A.

Paraoxonase activity and genetic variation in two paraoxonase genes (PON₁ and PON₂) in type₂ diabetes
pp. 15-15(1)
Authors: Letellier C.; Durou M.R.; Wojcik F.; Ruelland A.

Diabetes and obesity in CHD patients in the Asia-Pacific region: The ASPAC study
pp. 15-15(1)
Authors: Tan C.-E.; Ritchie G.; Lin K.; Janus E.; Kusmana D.; Keech A.; Asia-Pacific CHD Risk Factor Collaborative Group

Oxidative stress in families of type 1 diabetic patients
pp. 15-16(2)
Authors: Matteucci E.; Cinapri V.; Quilici S.; Forotti G.; Giampietro O.

Moderately elevated triglycerides are associated to insulin resistance (evaluated by HOMA) in normal-weight subjects with normal glucose tolerance
pp. 16-16(1)
Authors: Alessandrini P.; Moro E.; Gallina P.; Pais M.; BittoloBon G.

Delayed activation of nitric oxide synthase II in the aorta of streptozotocin-diabetic rats
pp. 16-16(1)
Authors: Nardi F.; Bolego C.; Cignarella A.; Puglisi L.

Homocysteine and lipid metabolism in children with type 1 diabetes
pp. 16-16(1)
Authors: Wiltshire E.; Couper J.; Thomas D.

Predictors of LDL particle size in type 2 diabetes
pp. 16-17(2)
Authors: Wagner A.M.; Perez A.; Jorba O.; Rigla M.; Sanchez J.L.; Ordonez J.

Fasting dysglycemia and coronary artery disease: Contribution of abdominal obesity and hypertriglyceridemia
pp. 17-17(1)
Authors: St-Pierre J.; Lemieux I.; Perron P.; Tremblay G.; Despres J.-P.; Gaudet D.

Plasma homocysteine in families of type 1 diabetic patients
pp. 17-17(1)
Authors: Matteucci E.; Rossi L.; Lucchetti A.; Quilici S.; Cinapri V.; Giampietro O.

Fluvastatin and fenofibrate in patients with isolated hypercholesterolaemia and mixed hyperlipidaemia and non-insulin-dependent diabetes mellitus
pp. 17-17(1)
Authors: Kozlov S.; Sarano N.; Tvorogova M.; Lyakishev A.; Naumov V.

B vitamins substantially reduce plasma homocysteine in patients with diabetes mellitus
pp. 17-17(1)
Authors: Levy Y.; Yeremenko Y.; Friedrich I.; Lavie L.

Metabolic syndrome in patients with NIDDM: Role in the development of global coronary events risk
pp. 17-18(2)
Authors: Mamedov M.N.; Khadipash L.A.; Perova N.V.; Oganov R.G.

Effect of doxazosin, a selective 1-adrenergic blocker, on the size of LDL particle size, in the type2 diabetic patients with hypertension
pp. 18-18(1)
Authors: Murakami H.; Tamasawa N.; Matsui J.; Hinata T.; Suda T.

Unsaturated, but not saturated, dietary fatty acids are associated with plasminogen activator inhibitor-1 (PAI-1) activity in men
pp. 18-18(1)
Authors: Byberg L.; Vessby B.; Lithell H.

Mechanisms of smooth muscle cell migration into fibrin gels
pp. 18-18(1)
Authors: Naito M.; Nomura H.; Kodama M.; Iguchi A.; Thompson W.D.; Smith E.B.

Protein kinase C- mediates the production of plasminogen activator inhibitor-1 in vascular endothelial cells induced by native or oxidized low density lipoprotein and lipoprotein(a)
pp. 18-18(1)
Authors: Ren S.; Shatadal S.; Shen G.

Platelet PAI-1 release and 4G/5G polymorphism of PAI-1 gene promoter in patients with coronary artery disease
pp. 19-19(1)
Authors: Jeng J.R.; Chu K.M.; Lin C.C.; Wang W.B.; Tsau D.P.; Yang S.P.

Novel method for determination of lower molecular weight fibrinogen in human plasma
pp. 19-19(1)
Authors: Lipinski B.; Lipinska I.

Effect of pyridoxal-5-phosphate on platelet aggregation in relation to intracellular calcium mobilization and adenosine-3-5'-cyclic monophosphate accumulation
pp. 19-19(1)
Authors: Chang S.-J.; Hsieh S.-Y.

Plasmin cleavage sites not detectable in fibrin within foamy macrophages of most human plaques
pp. 19-19(1)
Authors: Thompson W.D.; Stretton R.; Seath J.; McNally S.J.; Reid A.; Smith E.B.; Stirk C.M.; Melvin W.T.; Gaffney P.J.

Vitamins C and E reduce vascular PAI-1 expression after angioplasty in a model of porcine hypercholesterolemia
pp. 19-20(2)
Authors: Rodriguez J.A.; Orbe J.; Grau A.; Paramo J.A.; Martinez-Caro D.

Recombinant annexin II upregulates plasmin generation on endothelial cells
pp. 20-20(1)
Authors: Ishii H.; Yoshida M.; Yasukochi Y.; Hajjar K.A.; Tanaka A.; Numano F.

Activated factor XII and coronary artery calcification in type 1 diabetic patients and the general population
pp. 20-20(1)
Authors: Colhoun H.M.; Ford R.; Otvos J.; Rubens M.B.; Fuller J.H.

Alterations in the tissue factor pathway in hypertriglyceridemia do not cause a ''pro-coagulant state''; Effects of lipid lowering therapy by bezafibrate
pp. 20-20(1)
Authors: Jonkers I.J.A.M.; de Man F.H.A.F.; van der Laarse A.; Smelt A.H.M.; Bertina R.M.

Tissue factor expression and apoptosis induced by oxidized LDL on human umbilical endothelial cells are prevented by antioxidants
pp. 20-20(1)
Authors: Banfi C.; Giandomenico G.D.; Arpaia M.; Mussoni L.; Tremoli E.

Plasma levels of fibrinogen as a pathogenic factor or risk indicator of atherosclerosis
pp. 20-21(2)
Authors: Salvat N.; Villaverde C.A.; Pena E.; Corominas A.; Tibau N.

Influence of the fibrinolytic system in the regulation of extracellular matrix metalloproteases
pp. 21-21(1)
Authors: Villaverde C.A.; Pena E.; Corominas A.; Salvat N.; Tibau N.

The PLA1/A2 polymorphism of platelet glycoprotein IIIA is not associated with deep venous thrombosis
pp. 21-21(1)
Authors: Renner W.; Hoffmann C.; Koppel H.; Pabst E.; Brodmann M.; Schallmoser K.; Stanger O.; Wascher T.C.; Toplak H.; Pilger E.

Coagulation Factor V ARG506GLN: Myocardial infarction and longevity
pp. 21-21(1)
Authors: Juul K.; Tybjaerg-Hansen A.; Steffensen R.; Jensen G.; Nordestgaard B.G.

Thrombin upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: Role of several protein kinases and reactive oxygen species
pp. 21-22(2)
Authors: Bassus S.; Kronemann N.; Kirchmaier C.M.; Busse R.; Schini-Kerth V.B.

Effects of homocysteine on platelet aggregation in vitro
pp. 22-22(1)
Authors: Fan B.; Tomlinson B.; Thomas N.; Critchley J.

Adrenomedullin modulates the expression of tissue factor and tissue factor pathway inhibitor by human aortic endothelial cells
pp. 22-22(1)
Authors: Marutsuka K.; Asada Y.; Yamashita A.; Hatakeyama K.; Sato Y.; Sumiyoshi A.

Risk of ischaemic heart disease or ischaemic cerebral stroke and levels of fibrinogen and von Willebrand factor
pp. 22-22(1)
Authors: Jastrzbska M.; Torbus-Lisiecka B.; Pieczul-Mroz J.; Honczarenko K.; Chelstowski K.; Naruszewicz M.

Procoagulant activity of T lymphocytes due to exposure of negatively charged phospholipids - Role of lipid oxidation
pp. 22-22(1)
Authors: Barrowcliffe T.W.; Jardi M.; Rodriguez-Lambies N.; Fabregas P.; Felez J.

Impairment of prostacyclin-induced platelet inhibition in free radical-treated platelets
pp. 23-23(1)
Authors: Loreau N.; Blache D.

Pioglitazone upregulates the expression of thrombomodulin by THP-1 cells
pp. 23-23(1)
Authors: Oida K.; Tohda G.; Takahashi S.; Kosaka S.; Okada E.; Kanehara H.; Ishii H.; Miyamori I.

Carotid plaque measurement: An important tool for research as well as clinical management of atherosclerosis
pp. 23-23(1)
Author: Spence J.D.

Carotid and femoral intima media thickness and plaques in patients with familial hypercholesterolemia
pp. 23-23(1)
Authors: Smilde T.J.; Trip M.D.; Wollersheim H.; van Wissen S.; Kastelein J.J.P.; Stalenhoef A.F.H.

Effect of smoking cessation on arterial wall dynamics
pp. 23-24(2)
Authors: van den Berkmortel F.; Wollersheim H.; van Langen H.; Thien T.

Macrophages in carotid plaques predicted by ultrasound B-mode imaging
pp. 24-24(1)
Authors: Gronholdt M.-L.M.; Nordestgaard B.G.; Wiebe B.M.; Zhou J.; Bentzon J.; Falk E.; Sillesen H.

4D flow patterns in normal subjects vs patients with coronary artery disease
pp. 24-24(1)
Authors: Bogren H.; Buonocore M.

A novel polyiodinated compound for early detection of atherosclerosis
pp. 24-24(1)
Authors: Xiao W.; Scott T.; Wang L.; Yu Z.; Feng L.; Liu H.

Low dose metoprolol and fluvastatin in silent atherosclerotic disease: Metabolic and adverse effects in BCAPS
pp. 24-24(1)
Authors: Hedblad B.; Wikstrand J.; Janzon L.; Wedel H.; Berglund G.; BCAP study group

Carotid artery intima-media thickness in Finnish FCHL families
pp. 24-25(2)
Authors: Ylitalo K.; Salonen R.; Taskinen M.-R.; Salonen J.T.

Magnetization transfer as a contrast enhancing mechanism in magnetic resonance images of human atherosclerotic plaques
pp. 25-25(1)
Authors: Kerwin W.; Ferguson M.; Small R.; Hatsukami T.; Yuan C.

Early and intermediate lesions of atherosclerosis in the human carotid artery: Visualization by magnetic resonance imaging and assessment of imaging reproducibility
pp. 25-25(1)
Authors: Yuan C.; Zhang S.X.; Han C.; Hatsukami T.S.

The effect of vitamin E and vitamin C on 3-year progression of carotid atherosclerosis: The antioxidant supplementation in atherosclerosis prevention (ASAP) study
pp. 25-25(1)
Authors: Salonen J.T.; Nyyssonen K.; Salonen R.; Lakka H.-M.; Kaikkonen J.; Porkkala E.-S.; Voutilainen S.; Lakka T.A.; Rissanen T.; Leskinen L.; Tuomainen T.-P.; Valkonen V.-P.; Ristonmaa U.; Poulsen H.E.

Association of coronary risk factors and early stage of atherosclerosis in men
pp. 25-25(1)
Authors: Hashimoto M.; Akishita M.; Eto M.; Kozaki K.; Iijima K.; Ako J.; Kim S.; Toba K.; Yoshizumi M.; Ouchi Y.

Asymmetry of common carotid artery velocity is a marker for cardiovascular disease
pp. 25-26(2)
Authors: Nakano H.; Okazaki K.; Sato S.; Suzuki T.; Oba K.; Metori S.

Carotid atherosclerosis by B-mode ultrasound in the centenarians and the younger healthy subjects
pp. 26-26(1)
Authors: Homma S.; Ishida H.; Hirose N.; Ishii T.

Femoral atherosclerosis has a higher predictive value than carotid for detection of coronary heart disease
pp. 26-26(1)
Authors: Yerly P.; Depairon M.; Owlya R.; de Benedetti E.; Eeckhout E.; Brunner H.R.; Kappenberger L.; Darioli R.

Coronary calcification detected by mobile helical CT unit in a mass screening: The frequency and relationship to coronary risk factors and coronary artery disease
pp. 26-26(1)
Authors: Itani Y.; Watanabe S.; Takasu J.; Masuda Y.; Hanamura K.; Asakura K.; Sone S.; Sunami Y.; Shimura A.; Miyamoto T.

Long term change in atherosclerosis of human abdominal aorta observed by enhanced CT
pp. 26-26(1)
Authors: Tsushima M.; Ohara S.; Koh H.; Nishioeda Y.; Suzuki M.; Kyotani S.; Harano M.

Atherosclerotic plaque area by transesophageal echocardiography (TEE) related to coronary artery disease (CAD) and risk factors
pp. 27-27(1)
Authors: Kinoshita M.; Iwama Y.; Sugo A.; Ohashi S.; Sato H.; Kurata T.; Daida H.; Mokuno H.; Yamaguchi H.

The relationship of flow-dependent dilatation of the popliteal artery to common carotid artery intima media thickness
pp. 27-27(1)
Authors: Spacil J.; Ceska R.; Haas T.; Stulc T.; Horejsi B.

ACE and AT1R gene polymorphism in patients with ischaemic heart disease
pp. 27-27(1)
Authors: Goracy I.; Goracy J.; Adler G.; Ciechanowicz A.; Naruszewicz M.

Influence of plasmatic lipid levels on coronary atherosclerosis and remodeling as determined by 3 D intravascular imaging
pp. 27-27(1)
Authors: Gilard M.; Mansourati J.; Larlet J.M.; Touiza A.; Blanc J.J.; Boschat J.

Elevation of anti-helicobacter pylori antibody is a predictor of ischemic events in patients with coronary heart disease
pp. 27-28(2)
Authors: Tsai W.-C.; Li Y.-H.; Sheu B.-S.; Tsai L.-M.; Lin L.-J.; Chen J.-H.

Association of chlamydia pneumoniae infection with diabetes mellitus in patients with coronary artery disease
pp. 28-28(1)
Authors: Momiyama Y.; Hirano R.; Miyazaki K.; Kitagaki M.; Miyagawa T.; Hisada T.; Sawada S.; Yonemura A.; Higashi K.; Shibuya T.; Nakamura H.; Ohsuzu F.

Chlamydia pneumoniae seropositivity and Carotid Atherosclerosis - A Japanese population-based study
pp. 28-28(1)
Authors: Maeda N.; Hayashi J.; Sawayama Y.; Shimizu C.; Kashiwagi K.; Nakashima H.; Kashiwagi S.

Simvastatin reduces acute phase response markers
pp. 28-28(1)
Authors: Sinzinger H.; Chehne F.; Oguogho A.; Schmid P.

The association between antibody titers to helicobacter pylori, chronic coronary heart disease and acute myocardial infarction
pp. 28-28(1)
Authors: Sarraf-Zadegan N.; Amiri M.; Magsoodloo S.

Randomized double-blind, placebo-controlled study of azithromycin in C. Pneumoniae Positive Postmyocardial Infarction Patients (CROAATS)
pp. 28-29(2)
Authors: Reiner Z.; Bergovec M.; Gjurasin M.; Goldner V.; Halle J.; Kranjcevic S.; Mihatov S.; Zrnic T.; Culig J.; Tedeschi-Reiner E.; CROAATS Study Group

C-reactive protein: Associations with cardiovascular risk factors and all-cause mortality in elderly
pp. 29-29(1)
Authors: Hoekstra T.; Schouten E.; Kluft C.

Changes in plasma levels of inflammation markers, lipid profile and homocysteine following treatment with antibiotic in patients with chronic Chlamydia pneumoniae infection operated for ischaemic heart disease
pp. 29-29(1)
Authors: Brykczynski M.; Millo B.; Bukowska H.; Giedrys-Kalemba S.; Borowik-Puchala M.; Wiechowski S.; Naruszewicz M.

Plasma leptin and soluble TNF-receptors levels in relation to atherogenic and thrombogenic CVD risk factors among us men
pp. 29-29(1)
Authors: Chu N.-F.; Hotamisligil G.S.; Stampfer M.; Rimm E.B.

Concordant cell specific upregulation of cyclin-dependent kinase inhibitory of the CIP/KIP and ink4 families and SMAD-2 in fibrofatty human atherosclerotic lesions
pp. 29-29(1)
Authors: Kalinina N.I.; Tararak E.M.; Ilyinskaya O.P.; Agrotis A.; Bobik A.

Endogenous neutralising antibodies against Platelet-Derived Growth Factor-AA inhibit atherogenesis in the cholesterol-fed rabbit
pp. 30-30(1)
Authors: Lamb D.J.; Ferns G.A.A.

Angiotensin II increases macrophage uptake of Ox-LDL and CD36 mRNA expression: Possible role of IL-6 and inhibitory effects of fosinopril and losartan
pp. 30-30(1)
Authors: Keidar S.; Heinrich P.

Functional diversity of platelet derived growth factor receptor and in atherogenesis in vivo
pp. 30-30(1)
Authors: Sano H.; Yokode M.; Sudo T.; Takakura N.; Kataoka H.; Murayama T.; Nishikawa S.; Nishikawa S.-I.; Kita T.

Osteopontin stimulates Mitogen-activated Protein Kinases (MAPK) and Cell Growth through Activation of v3 integrin in human endothelial cells
pp. 30-30(1)
Authors: Mogi M.; Fukuo K.; Ogihara T.

Homocysteine-induced expression of monocyte chemoattractant protein-1 expression in THP-1 is mediated by nuclear factor-B activation
pp. 30-31(2)
Authors: O K.; Wang G.

Carbon monoxide and nitric oxide-mediated induction of VEGF synthesis in vascular smooth muscle cells
pp. 31-31(1)
Authors: Dulak J.; Jozkowicz A.; Foresti R.; Green C.; Motterlini R.; Pachinger O.; Weidinger F.

Effects of cerivastatin on monocyte gene expression
pp. 31-31(1)
Authors: Bruegel M.; Teupser D.; Stein O.; Stein Y.; Thiery J.

Pro-inflammatory response induced through intestinal derived small triglyceride rich particles (TRP) in adult-onset growth hormone deficiency (AGHD)
pp. 31-31(1)
Authors: Twickler T.B.; Visseren F.L.J.; Dallinga-Thie G.M.; van Dam P.S.; Cabezas M.C.; Koppeschaar H.P.F.; Erkelens D.W.

Association of IL-1RA gene polymorphism to future stroke
pp. 31-31(1)
Authors: Trifunovic J.; Wiklund P.G.; Ahmed E.; Weinehall L.; Hallmans G.; Lefvert A.K.

Regulation of macrophage lipoprotein lipase gene expression
pp. 31-32(2)
Authors: Ramji D.P.; Hughes T.R.; Mead J.R.; Irvine S.A.; Cryer A.

Exaggerated vascular remodeling in the mice lacking angiotensin II type 2 receptor
pp. 32-32(1)
Authors: Akishita M.; Horiuchi M.; Dzau V.J.; Ouchi Y.

Chylomicron remnant induces monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells through an activation of p38 MAPK
pp. 32-32(1)
Authors: Domoto K.; Taniguchi T.; Takahashi T.; Kawasaki S.; Taguchi M.; Matsuo Y.; Takahashi Y.; Fujioka Y.; Ishikawa Y.; Yokoyama M.

Requirement of intact actin cytoskeleton for Angiotensin II-stimulated tyrosine kinase pathways in vascular smooth muscle cells
pp. 32-32(1)
Authors: Takahashi T.; Taniguchi T.; Domoto K.; Taguchi M.; Matsuo Y.; Takahashi Y.; Ishikawa Y.; Yokoyama M.

Regulation of PDGF-R mRNA expression by IFN and IFN
pp. 32-33(2)
Authors: Morelli P.I.; Pettersson S.; Fager G.; Bondjers G.; Lustig F.

25-Hydroxycholesterol increases a hypoxia induced IL-8 protein secretion in human macrophages
pp. 33-33(1)
Authors: Rydberg E.K.; Salomonsson L.; Bjornheden T.; Wiklund O.; Bondjers G.; Ohlsson B.G.

Oxidised LDL increases the VEGF expression in human macrophages
pp. 33-33(1)
Authors: Salomonsson L.; Wiklund O.; Bondjers G.; Ohlsson B.G.

Disruption of tumor necrosis factor- gene prevents the development of atherosclerosis in apoE-deficient mice
pp. 33-33(1)
Authors: Fujii H.; Wada H.; Saito K.; Maekawa N.; Fujigaki S.; Kirii H.; Sekikawa K.; Seishima M.

Binding of platelet derived growth factor (PDGF) isoforms on chinese hamster ovarian (CHO) K1 cells and human smooth muscle cells (hSMC)
pp. 33-33(1)
Authors: Olivas R.G.; Krettek A.; Fager G.; Lustig F.; Reina M.; Vilaro S.

A common 936 C/T mutation in the gene for vascular endothelial growth factor (VEGF) is associated with VEGF plasma levels
pp. 33-34(2)
Authors: Renner W.; Kotschan S.; Hoffmann C.; Obermayer-Pietsch B.; Pilger E.

Atorvastatin reduces NF-B activity and the expression of Interleukin-8, Metalloproteinase-3 and Cyclooxygenase-2 in a rabbit model of atherosclerosis
pp. 34-34(1)
Authors: Hernandez-Presa M.A.; Tunon J.; Ortego M.; Mas S.; Martin-Ventura J.L.; Blanco-Colio L.; Gomez-Hernandez A.; Bustos C.; Aparicio C.; Ortega L.; Gomez-Gerique J.; Porres A.; Diaz C.; Hernandez G.; Egido J.

Peroxisome proliferator-activated receptors- (PPAR) Increase the generation of VEGF
pp. 34-34(1)
Authors: Jozkowicz A.; Placha W.; Dulak J.; Piatkowska E.; Dembinska-Kiec A.

The Jagged/Notch expression in the VEGF165, bFGF and leptin induced angiogenesis in 3D collagen I model
pp. 34-34(1)
Authors: Dembinska-Kiec A.; Polus A.

Interleukin-6 (IL-6) stimulates LDL-receptor gene expression via activation of the SREBP and the Sp1 family of transcription factors in HepG2 cells
pp. 34-35(2)
Authors: Gierens H.; Nauck M.; Schinker R.; Schurmann C.; Scharnagl H.; Wieland H.; Marz W.

The upregulation of the MCP-1 in the vascular wall can be prevented by statins independently of plasma cholesterol levels
pp. 35-35(1)
Authors: Martinez-Gonzalez J.; Alfon J.; Badimon L.

Pravastatin prevents postprandial hyper- and dislipidaemiia in patients with CHD
pp. 35-35(1)
Authors: Aronov D.M.; Bubnova M.G.; Perova N.B.; Zhasminova V.G.; Golubev M.A.

The effect of fluvastatin on catheter-induced intimal thickening in normocholesterolemic rabbits
pp. 35-35(1)
Authors: Ye P.; Yu D.C.; Song L.G.

Pravastatin stabilize fibrous caps of coronary plaques of WHHL rabbits
pp. 35-35(1)
Authors: Shiomi M.; Ito T.; Hirouchi Y.; Enomoto M.

Statin therapy in hyperlipidaemia induces reduction of coagulation activation in the first month of therapy
pp. 35-36(2)
Authors: Korte W.; Riesen W.; Noseda G.

Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia
pp. 36-36(1)
Authors: Geiss H.C.; Parhofer K.G.; Schwandt P.

Lipid-lowering therapy with cerivastatin improves endothelial function after 2 weeks
pp. 36-36(1)
Authors: Schmieder R.E.; Jacobi J.; Delles C.; Schlaich M.P.; Schneider M.; John S.

Efficacy and safety of cerivastatin/bezafibrate and cerivastatin/fenofibrate combination therapies
pp. 36-36(1)
Authors: Farnier M.; Esper R.

Determination of mRNA levels of cholesterol regulatory proteins in cultured human cells using ribonuclease protection assay
pp. 36-37(2)
Authors: Morikawa S.; Murakami T.; Tamaki T.; Kitahara M.; Saito Y.; Hamakubo T.; Kodama T.

The relative induction of mRNA for HMGCoA and LDL receptor by five different HMGCoA reductase inhibitors in cultured human cells
pp. 37-37(1)
Authors: Morikawa S.; Umetani M.; Nakagawa S.; Yamazaki H.; Suganami H.; Inoue K.; Kitahara M.; Hamakubo T.; Kodama T.; Saito Y.

Pravastatin use and risk of coronary events and cerebral infarction in Japanese men with hypercholesterolemia: The Kyushu Lipid Intervention Study (KLIS)
pp. 37-37(1)
Authors: Sasaki J.; Arakawa K.; KLIS group

Plasma fibrinogen behavior during treatment of hypercholesterolemia with simvastatin
pp. 37-37(1)
Authors: Tortora A.; Parafioriti E.; Ilutovich S.; Slater H.

Reduced expression of soluble markers of endothelial dysfunction after 1 year treatment with atorvastatin and simvastatin in patients with coronary heart disease
pp. 37-37(1)
Authors: Seljeflot I.; Tonstad S.; Hjermann I.; Kleve R.; Arnesen H.

ApoA-1, but not total cholesterol and LDL-C, is predictive for myocardial infarction (MI) and death in patients with coronary artery disease (CAD) and treated lipid levels
pp. 37-38(2)
Authors: Roeters van Lennep J.; Westerveld H.; Roeters van Lennep H.; Zwinderman A.; Erkelens W.; van der Wall E.

Predictors of glucose intolerance (GI) in the West of Scotland Coronary Prevention Study (WOSCOPS)
pp. 38-38(1)
Authors: Freeman D.J.; Norrie J.; Sattar N.; Neely R.D.G.; Cobbe S.M.; Ford I.; Isles C.; Lorimer A.R.; Macfarlane P.W.; McKillop J.H.; Packard C.J.; Shepherd J.; Gaw A.

Muscle pains and/or CK-elevation during HMG-CoA-reductase inhibitor therapy are frequently associated with increased isoprostane
pp. 38-38(1)
Authors: Sinzinger H.; Lupattelli G.; Chehne F.; Oguogho A.; Furberg C.D.

Effect of simvastatin on remnant lipoproteins in heterozygous familial hypercholesterolaemia
pp. 38-38(1)
Authors: Dane-Stewart C.A.; Watts G.F.; Mamo J.C.L.; Redgrave T.G.; Barrett P.H.R.; Dimmitt S.

-491 A/T polymorphism in the apo E gene promoter region modulates the lipid lowering response to atorvastatin and bezafibrate in patients with mixed dyslipidemia
pp. 38-38(1)
Authors: Garcia-Otin A.L.; Civeira F.; Aristegui R.; Masramon X.; Diaz C.; Hernandez G.; Pocovi M.; ATOMIX Study Group

Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
pp. 39-39(1)
Authors: Olsson A.G.; Pears J.S.; McKellar J.; Caplan R.J.; Raza A.

Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522
pp. 39-39(1)
Authors: Warwick M.J.; Dane A.L.; Raza A.; Schneck D.W.

Pharmacological properties of ZD4522 - A new HMG-CoA reductase inhibitor
pp. 39-39(1)
Authors: Smith G.; Davidson R.; Bloor S.; Burns K.; Calnan C.; McAulay P.; Torr N.; Ward W.; McTaggart F.

Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
pp. 39-39(1)
Authors: Nezasa K.; Higaki K.; Hasegawa H.; Inazawa K.; Takeuchi M.; Yukawa T.; McTaggart F.; Nakano M.

Effect of simvastatin on plasma C-reactive protein and fibrinogen: A randomised controlled trial
pp. 40-40(1)
Authors: MacMahon M.; Kirkpatrick C.; Cummings C.E.; Clayton A.; Robinson P.; Tomiak R.; Liu M.; Kush D.; Tobert J.

Acute inhibition of VLDL-apoB secretion by atorvastatin in primary hamster hepatocytes
pp. 40-40(1)
Authors: Cavallo D.; Taghibiglou C.; Van Iderstine S.; Mangaloglu L.; Kazemian P.; Pontrelli L.; Cheung R.; Adeli K.

Effect of fluvastatin on antioxidant activity of plasma in patients with stable angina with average cholesterol levels
pp. 40-40(1)
Authors: Kowalski J.; Olejniczaki J.; Kedziora J.; Blaszczyk J.; Bartosz G.

Simvastatin (Zocor^&unknown;) induces the expression of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes
pp. 40-40(1)
Authors: Gratl V.; Chen B.; Taghibiglou C.; Van-Iderstine S.; Cheung R.; Adeli K.

The association between LDL-C and outcome: The pravastatin pooling project
pp. 40-41(2)
Authors: Ford I.; Craven T.; Furberg C.; Byington R.; Tonkin A.; Simes J.; Sacks F.; Braunwald E.; Pravastatin Pooling Project investigators

Prospective pravastatin pooling project: Relative risk reduction by baseline HDL and TG concentrations
pp. 41-41(1)
Authors: Sacks F.; Tonkin A.; Shepherd J.; Braunwald E.; Cobbe S.; Hawkins M.; Keech A.; Packard C.; Simes J.; Byington R.; Furberg C.; Pravastatin Pooling Project Investigators

Simvastatin increases plasma levels of the anti-oxidant enzyme paraoxonase by PON1 gene activation
pp. 41-41(1)
Author: James L.R.

Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells
pp. 41-41(1)
Authors: Buckett L.; Ballard P.; Davidson R.; Dunkley C.; Martin L.; Stafford J.; McTaggart F.

Increased levels of oxidized LDL in obese patients are normalised by treatment with atorvastatin
pp. 41-42(2)
Authors: Mertens A.; Muls E.; Vansant G.; Collen D.; Holvoet P.

No effect of simvastatin treatment on C-reactive protein in patients with familial hypercholesterolemia
pp. 42-42(1)
Authors: Mohrschladt M.F.; de Maat M.P.M.; Westendorp R.G.J.; Smelt A.H.M.

Alleles of high active paraoxonase R/Q192 polymorphisms are associated with HDL-cholesterol increasing effect of pravastatin
pp. 42-42(1)
Authors: Laaksonen R.; Malin R.; Janatuinen T.; Vesalainen R.; Knuuti J.; Lehtimaki T.

HMG-CoA reductase inhibitor reduces monocyte adhesion to vascular endothelium under physiological flow conditions
pp. 42-42(1)
Authors: Yoshida M.; Gerszten R.E.; Rosenzweig A.; Gimbrone M.A.; Yasukochi Y.; Numano F.

A new method to evaluate the lipid lowering effect of drugs on lipoprotein metabolism using agarose gel electrophoresis
pp. 42-42(1)
Authors: Kurata H.; Utsunomiya K.; Kido T.; Taniguchi K.; Terashima M.; Kamata N.; Tobiyama R.; Nakazato T.; Itakura H.; Kondo K.; Tajima N.

Effects of fluvastatin on angiotensin II induced superoxide formation in human aortic smooth muscle cell
pp. 42-43(2)
Authors: Kugi M.; Matsunaga A.; Huang W.; Han H.; Ono J.; Arakawa K.; Sasaki J.

Differences in effects of pravastatin and simvastatin (40 mg/day) on total serum cholesterol, 24s-hydroxycholesterol and 27-hydroxycholesterol
pp. 43-43(1)
Authors: Locatelli S.; Lutjohann D.; von Bergmann K.

Effect of high dose simvastatin on plasma concentrations of homocyst(e)ine
pp. 43-43(1)
Authors: Lutjohann D.; von Bergmann K.

Effect of atorvastatin on platelet function in patients with hypercholesterolemia
pp. 43-43(1)
Authors: Sanguigni V.; Caccese D.; Magnaterra R.; Ferrara E.; Mazzolini S.; De Vito F.; Violi F.; Lauro R.

Treatment of simvastatin in hypercholesterolemia induces changes in the coagulation system
pp. 43-43(1)
Authors: Chojnowska-Jezierska J.; Broncel M.; Michalska M.; Kostka B.

Effect of simvastatin on serum lipids and erythrocyte membrane in patients with hypercholesterolemia type II
pp. 44-44(1)
Authors: Broncel M.; Chojnowska-Jezierska J.; Koter M.; Franiak I.

Prognostic assessment of patients with coronary heart disease: Results from the LIPID study
pp. 44-44(1)
Authors: Colquhoun D.; Marschner I.; Simes J.; Glasziou P.; Keech A.

Reduction in coronary events with pravastatin and proportion of treatment benefit explained by on-study LIPID levels in the LIPID study
pp. 44-44(1)
Authors: Simes J.; Marschner I.; Hunt D.; Colquhoun D.; Glasziou P.; Hague W.; MacMahon S.; Keech A.; Tonkin A.; LIPID Study Group

Effects of pravastatin on cardiovascular endpoints in patients with previous unstable angina
pp. 44-44(1)
Authors: Tonkin A.; Becker S.; Hunt D.; Keech A.; Lane G.; White H.; Hague W.; Simes J.; LIPID Study Group

Effect of different doses of atorvastatin and atorvastatin/pravastatin in patients undergoing regular LDL-Apheresis
pp. 44-45(2)
Authors: Schettler V.; Blanckenberg A.; Wieland E.; Schuff-Werner P.; Muller G.A.

Potent inhibition of human LDL and membrane oxidative damage by the hydroxy metabolite of atorvastatin
pp. 45-45(1)
Author: Mason R.P.

Effect of atorvastatin (Lipitor&unknown;) on VLDL-apoB and VLDL-triglyceride overproduction in vivo in an insulin resistant hamster model
pp. 45-45(1)
Authors: Mangaloglu L.; Van-Iderstine S.; Chen B.; Taghibiglou C.; Cheung R.; Adeli K.

Stimulation of nitric oxide synthase by HMG-CoA reductase inhibitors
pp. 45-45(1)
Authors: Marz W.; Tisljar U.; Scharnagl H.; Gierens H.; Wieland H.

Effect of statin therapy on HDL-C levels in patients with type IIa and type IIb hyperlipidemia
pp. 45-45(1)
Authors: Nawrocki J.W.; Peters T.K.

Effect of atorvastatin and simvastatin in obtaining targets for lipids in secondary prevention. The treat-to-target study (3T)
pp. 46-46(1)
Authors: Olsson A.G.; Eriksson M.; Johnson O.; Kjellstrom T.; Lanke J.; Lytken Larsen M.; Pedersen T.R.; Tikkanen M.J.; Wiklund O.; 3 T investigators

Effects of HMG-CoA reductase inhibitors on endotoxin induced release of TNF and IL-6 in whole blood system
pp. 46-46(1)
Authors: Fraunberger P.; Jaeger B.R.; Faist E.; Groene H.J.; Walli A.K.; Seidel D.

Simvastatin treatment lowers postprandial lipemia in CHD patients
pp. 46-46(1)
Authors: Mezo I.; Reiber I.

Effects of atorvastatin versus fenofibrate on lipoprotein production and catabolic rate in patients with combined hyperlipidemia
pp. 46-46(1)
Authors: Bilz S.; Wagner S.; Bedynek A.; Demant T.; Keller U.

Short term effect of atorvastatin on plasma levels of MCP-1, ICAM-1 and C-reactive protein in patients with coronary artery disease
pp. 46-46(1)
Authors: Figueredo A.; Reinares L.; Rueda A.; Pontes J.C.; Rodriguez A.; Ruiz-Yague M.; Diaz C.; Pueyo C.; Hernandez G.; Fernandez-Cruz A.; Patino R.

Analysis of factors that influence the C-reactive protein (CRP) lowering effect of atorvastatin and bezafibrate in mixed dyslipidemia (the ATOMIX Study)
pp. 47-47(1)
Authors: Aristegui R.; Gomez Gerique J.A.; Diaz C.; Masramon X.; Sol J.M.; Hernandez G.; ATOMIX Study Group

Evidence of a relationship between the increase of HDL cholesterol and the decrease of serum triglycerides and LDL cholesterol after simvastatin
pp. 47-47(1)
Authors: Branchi A.; Fiorenza A.M.; Torri A.; Muzio F.; Rovellini A.; Sommariva D.

The effects of atorvastatin and fenofibrate on the levels of malonyldialdehyde, homocysteine and the size of LDL particles in combined hyperlipidaemia
pp. 47-47(1)
Authors: Melenovsky V.; Malik J.; Wichterle D.; Simek J.; Ceska R.; Skrha J.; Parizkova A.; Poledne R.

Effect of atorvastatin 10 mg and of simvastatin 20 mg on serum triglyceride level
pp. 47-47(1)
Authors: Branchi A.; Fiorenza A.M.; Torri A.; Muzio F.; Rovellini A.; Berra C.; Sommariva D.

Cohort study of 132 patients on statin-niacin combination therapy for dyslipidemia
pp. 48-48(1)
Authors: Duvall W.L.; Blazing M.A.; Saxena S.; Guyton J.R.

Efficacy of pravastatin in reducing plasma LDL-cholesterol and LDL-apo B concentrations in mixed hyperlipidemias of different genetic causes
pp. 48-48(1)
Authors: Lamarche B.; St-Pierre A.; Julien P.; Bergeron J.; Perron P.; Gaudet D.

Effect of atorvastatin and bezafibrate on C-reactive protein in mixed dislipidemia (the ATOMIX Study)
pp. 48-48(1)
Authors: Gomez Gerique J.A.; Aristegui R.; Diaz C.; Masramon X.; Sol J.M.; Hernandez G.; ATOMIX Study Group

Effects of simvastatin and atorvastatin on total and fractionated HDL cholesterol
pp. 48-48(1)
Authors: Otvos J.; Cromwell W.; Alexander C.; Landsman P.; Kush D.; Mercuri M.

Effect of itavastatin on lipid metabolism in NIDDM patients with hyperlipidemia
pp. 48-49(2)
Authors: Yamada N.; Saito Y.; Akanuma Y.

Baseline lipid and lipoprotein concentrations in the participants of the prospective study of pravastatin in the elderly at risk (prosper)
pp. 49-49(1)
Authors: Gaw A.; Packard C.J.; PROSPER Executive

Atorvastatin and plasma homocysteine levels in subjects with familial hypercholesterolemia (FH)
pp. 49-49(1)
Authors: Bertolotto A.; Pucci L.; Bandinelli S.; Lucchesi D.; Navalesi R.; Penno G.

Efficacy and safety of the extended-release formulation of fluvastatin
pp. 49-49(1)
Authors: McKenney J.; Ballantyne C.; Trippe B.; Manfreda S.

HDL and triglyceride response with statins differ in their determinants and between drugs
pp. 49-49(1)
Authors: Wierzbicki A.; Lumb P.; Chik G.; Crook M.

Hyperfibrinogenaemia induced by statins correlates with drug therapy and cardiovascular risk factors
pp. 49-50(2)
Authors: Wierzbicki A.; Lumb P.; Chik G.; Crook M.

A HMG-CoA reductase inhibitor retards progression of atherosclerosis and regressed atherosclerosis in the rabbit aorta through a no mediated system
pp. 50-50(1)
Authors: Hayashi T.; Ito I.; Kano H.; Sumi D.; Thakur N.K.; Iguchi A.

Factors determining inter-individual variability of response to statin therapy
pp. 50-50(1)
Authors: Naoumova R.P.; O'Neill F.H.; Bourbon M.; Neuwirth C.K.Y.; Patel D.D.; Knight B.; Axelson M.; Thompson G.R.

Studies on the metabolic fate of itavastatin, a new inhibitor of HMG-CoA reductase-in vitro metabolism
pp. 50-50(1)
Authors: Fujino H.; Yamada I.; Shimada S.; Matsumoto H.; Yoneda M.

Effect of itavastatin on postprandial triglyceride levels and lymph chylomicron in rats
pp. 50-50(1)
Authors: Aoki T.; Yoshinaka Y.; Suzuki H.; Tamaki T.; Sato F.; Kitahara M.; Saito Y.

Hypolipidemic effect of itavastatin and other statins in guinea pigs
pp. 51-51(1)
Authors: Suzuki H.; Yamazaki H.; Aoki T.; Tamaki T.; Sato F.; Kitahara M.; Saito Y.

Fluvastatin: Extended-release vs immediate-release formulation
pp. 51-51(1)
Authors: Mancini M.; Olsson A.G.; Palacios B.; Pauciullo P.

Effect of immediate start with statins after acute myocardial infarction (AMI) on the reoccurrence of cardiovascular events during the following year
pp. 51-51(1)
Authors: Noto A.T.W.; Steffensen L.; Nordoy A.; Hansen J.B.

Efficacy of atorvastatin compared with fenofibrate in patients with combined hyperlipidemia
pp. 51-51(1)
Authors: Farnier M.; Maigret P.; Turpin G.; French Study Group

Atorvastatin 20 mg/day in the treatment of patients with familial hypercholesterolaemia: Effect on lipids and endothelial dysfunction
pp. 51-52(2)
Authors: Sussekov A.; Balakhonova T.; Pogorelova O.; Tvorogova M.; Atkov O.; Titov V.; Kukharchuk V.

Comparison of fluvastatin 80 mg extended-release and 40 mg immediate-release formulations
pp. 52-52(1)
Authors: Davidson M.; Hunninghake D.; Knapp H.; Manfreda S.

The effects of pravastatin treatment in patients with different ranges of plasma triglyceride levels
pp. 52-52(1)
Authors: Santos R.; Nascimento L.O.; Sposito A.C.; Massud J.; Maranhao R.C.

Liver function abnormalities in hyperlipidemic patients before and after hypolipidemic treatment
pp. 52-52(1)
Authors: Nikas S.; Chatzidimou K.; Milionis H.; Katsaraki A.; Bairaktari E.; Rizos E.; Tzallas C.; Kakafika A.; Kiortsis D.; Goudevenos I.; Elisaf M.

The effect of atorvastatin lipid-lowering therapy in smoker and nonsmoker patient with hyperlipoproteinemia
pp. 52-52(1)
Authors: Vulic D.; Keric L.; Vulic B.; Pavic Z.; Kostic S.; Ristic S.; Bajic S.

Long-term effects of NK-104 (itavastatin), a new HMG-CoA reductase inhibitor, in patients with heterozygous familial hypercholesterolemia
pp. 53-53(1)
Authors: Mabuchi H.; Hokuriku FH Study Group

Clinical evaluation of NK-104 (itavastatin) in long-term treatment of patients with hyperlipidemia
pp. 53-53(1)
Authors: Teramoto T.; Saito Y.; Nakaya N.; Japan Itavastatin Clinical Study Group

Lipid-altering efficacy and safety of simvastatin in women and elderly patients with hypercholesterolemia
pp. 53-53(1)
Authors: Kastelein J.J.P.; Ose L.; Stepanavage M.E.; Melino M.R.; Mitchel Y.B.

Metal-catalyzed oxidation of apolipoprotein B-100 forms 5-hydroxy-2-amino valeric acid as a specific marker of oxidative attack on arginine and proline residues
pp. 53-53(1)
Authors: Pietzsch J.; Julius U.

Oxidative stress and apolipoprotein C-III in binary system predicts the levels of risk for atherosclerosis in normolipidemic and hypertriglyceridemic subjects
pp. 53-54(2)
Authors: Lee D.M.; Purdie N.; Gibson C.K.; Simpson N.; Alaupovic P.

Inhibition of low-density lipoprotein (LDL) lipid peroxidation by policosanol, a new cholesterol-lowering agent
pp. 54-54(1)
Authors: Menendez R.; Mas R.; Amor A.M.; Gonzalez R.M.; Fernandez J.C.; Rodeiro I.; Zayas M.; Jimenez S.

Mechanism of the antioxidant to prooxidant switch for dehydroascorbate in low density lipoprotein oxidation
pp. 54-54(1)
Authors: Horsley E.T.M.; Harris L.K.; Moss N.J.; Leake D.S.

Mechanisms by which cysteine can inhibit or promote the oxidation of low density lipoprotein by copper
pp. 54-54(1)
Authors: Patterson R.A.; Lamb D.J.; Leake D.S.

In vivo complex formation of modified alpha1-antitrypsin with LDL
pp. 54-54(1)
Authors: Mashiba S.; Wada Y.; Takeya M.; Sugiyama A.; Hamakubo T.; Kodama T.; Uchida K.

Induction of gene expression by phenolic antioxidants, BO-653 and probucol and BHQ in human endothelial cells
pp. 54-55(2)
Authors: Takabe W.; Mataki C.; Wada Y.; Ishii M.; Okutani Y.; Cynshi O.; Noguchi N.; Aburatani H.; Hamakubo T.; Kodama T.; Niki E.

Serum bilirubin and albumin levels are markers of the extent of atherosclerosis in dyslipidaemic patients
pp. 55-55(1)
Authors: Papadakis J.A.; Ganotakis E.S.; Vrentzos G.; Emmanouel D.; Mikhailidis D.P.

Measurement of paraoxonase (PON) concentrations in coronary heart desease (CHD) subjects by sandwich Elisa
pp. 55-55(1)
Authors: Kujiraoka T.; Ishihara M.; Fujioka T.; Saito E.; Saito S.; Egashira T.; Hattori H.

Rapid isolation of VLDL subfractions: Assessment of composition and susceptibility to oxidation
pp. 55-55(1)
Authors: McEneny J.; Trimble E.R.; Young I.S.

Evidence of ATP and glucose depleted areas within the atherosclerotic plaque in vivo
pp. 55-55(1)
Authors: Levin M.; Evaldsson M.; Wiklund O.; Bondjers G.; Bjornheden T.

Modification of high density lipoproteins: Effects on OxLDL cytotoxicity and on cholesterol efflux
pp. 55-56(2)
Authors: Pirillo A.; Uboldi P.; Marcovina S.; Catapano A.L.

Oxidized LDL induce the release of thioredoxin,a chemoattractant, in human endothelial cells. Antagonistic effect of HDL
pp. 56-56(1)
Authors: Norata G.D.; Catapan A.L.

Fibrillar C-terminal fragment of alpha-1-antitrypsin activates human monocytes via oxidative mechanisms
pp. 56-56(1)
Authors: Janciauskiene S.; Lindgren S.

Oxidized LDL triggers the lysis of human macrophages concurrently to but independently of the induction of apoptosis by depleting intracellular ATP
pp. 56-56(1)
Authors: Asmis R.; Jelk J.; Wintergerst E.S.; Stark C.; Brawand F.

Foam cell formation reduces cellular vitamin E and increases the susceptibility of human macrophages to lysis by oxidized LDL
pp. 56-56(1)
Authors: Asmis R.; Jelk J.

Platelet activation by oxygen free radicals in hypercholesterolemic patients
pp. 57-57(1)
Authors: Sanguigni V.; Caccese D.; Magnaterra R.; Ferrara E.; Mazzolini S.; De Vito F.; Violi F.; Lauro R.

Paraoxonase (PON1) & coronary heart disease (CHD)
pp. 57-57(1)
Authors: Mackness B.; Durrington P.N.; Turkie W.; Davies G.K.; Mackness M.I.

The influence of different doses n-3 fatty acids (n-3 FA) with and without supplementation of vitamin E (vit E) on the levels of reactive oxygen species (ROS) in circulating human leukocytes
pp. 57-57(1)
Authors: Olsen H.; Seljeflot I.; Lyberg T.; Arnesen H.

Increased leukocyte levels of reactive oxygen species (ROS) in populations at risk for atherosclerotic disease
pp. 57-57(1)
Authors: Olsen H.; Seljeflot I.; Kahler H.; Larsen J.; Arnesen H.; Lyberg T.

Hemolysis increases atherogenesis despite induction of hemoxygenase in cholesterol-fed rabbits
pp. 57-58(2)
Authors: Fernandez A.; Lopez F.; Hurt-Camejo E.; Romano E.; Camejo G.; Apitz R.

The expression of human ATP-binding cassette transporter 1 mRNA increased by oxidized LDL
pp. 58-58(1)
Authors: Wanaka Y.; Boh-oka S.; Sakai Y.; Hamada M.; Hano T.; Nishio I.

An oxidized derivative of cholesterol increases the release of soluble vascular cell adhesion molecule-1 from human umbilical vein endotherial cells in culture
pp. 58-58(1)
Authors: Tamasawa N.; Murakami H.; Matsui J.; Imaizumi T.; Satoh K.; Suda T.

Protective role of phospholipase A2 in processes of LDL modification
pp. 58-58(1)
Authors: Korotaeva A.A.; Cheglakov I.B.; Golovanova N.K.; Vlasik T.N.; Yanushevskaya E.V.; Tsibulsky V.P.; Yakushkin V.V.; Prokazova N.V.

Oral vitamin B₁₂ lowers homocysteine in patients with ESRD more effectively in the homozygous T/T MTHFR 677 patients
pp. 58-58(1)
Authors: Hyndman M.E.; Manns B.; Bridge P.; Scott-Douglas N.; Burgess E.; Schaefer J.; Parsons H.

Oxidized low density lipoprotein induces reactive oxygen species in endothelial cells: Effect on the intracellular nitric oxide availability
pp. 58-59(2)
Authors: Cominacini L.; Rigoni A.; Garbin U.; Pasini A.F.; Davoli A.; Campagnola M.; Tosetti M.L.

Carnitines inhibits oxygen free radical release by endothelial cell and leukocytes
pp. 59-59(1)
Authors: Caroselli C.; Rossi E.; Loffredo L.; Picca A.; Natoli S.; Violi F.

Pro- and anti-oxidative activities of human monocytes: Effect of concentration of oxidatively modified low density lipoprotein
pp. 59-59(1)
Authors: Hulten L.M.; Markstrom E.; Pettersson S.; Dahlgren C.; van Reyk D.; Ullstrom C.; Wiklund O.

Oxidized low density lipoprotein (OxLDL) induces an increase in nuclear Ca²⁺ in cultured but not freshly isolated smooth muscle cells (VSMC)
pp. 59-59(1)
Authors: Massaeli H.; Austria J.A.; Hurtado C.; Pierce G.N.

The formation of probucol and alpha-tocopherol radicals and model of oxidative stress, influence of ubiquinol-10
pp. 59-59(1)
Authors: Ruuge E.K.; Shumaev K.B.; Gomboeva S.B.; Kukharchuk V.V.

Nuclear accumulation of cell cycle proteins in response to oxidized low density lipoprotein
pp. 59-60(2)
Authors: Zettler M.E.; Austria J.A.; Pierce G.N.

Oxidized phospholipids activate PPAR in a phospholipase A2-dependent manner
pp. 60-60(1)
Authors: Delerive P.; Furman C.; Teissier E.; Fruchart J.-C.; Duriez P.; Staels B.

Atorvastatin and simvastatin interfere with NF-B pathway activation elicited by reactive oxygen species in vascular smooth muscle cells and monocytes through a decrease in IB- phosphorylation
pp. 60-60(1)
Authors: Ortego M.; Hernandez-Presa M.A.; Blanco-Colio L.M.; Gomez-Hernandez A.; Martin-Ventura J.L.; Tunon J.; Diaz C.; Hernandez G.; Egido J.

*NO and peroxinitrite in hypercholesterolemia
pp. 60-60(1)
Authors: Moriel P.; Rubbo H.; Radi R.; Bertolami M.C.; Abdalla D.S.P.

Lipoprotein subfractions, antioxidant content and activation of platelet adhesion
pp. 60-60(1)
Authors: Hartwich J.; Gruca A.; Jopek R.; Niedbal S.; Golabek I.; Malczewska-Malec M.; Dembinska-Kiec A.

Homocyst(e)ine increase the functional expression of the macrophage receptor CD36
pp. 60-61(2)
Authors: Naruszewicz M.; Han J.; Nicholson A.C.; Hajjar D.P.

Oxidative stress in cholesterol fed rabbits
pp. 61-61(1)
Authors: Oikawa S.; Hirayama Y.; Sekikawa A.; Tokita Y.; Hara T.; Ishigaki Y.; Kotake H.; Toyota T.; Miyazawa T.

Opposite atherogenic effects of oxidised LDL on apolipoprotein AI and B synthesis in HEPG2 cells
pp. 61-61(1)
Authors: Bourdon E.; Loreau N.; Davignon J.; Bernier L.; Blache D.

Treatment with natural anti-oxidants from vitis vinifera decreases lipid peroxidation in non insulin-dependent diabetics
pp. 61-61(1)
Authors: Zoppo A.; Viappiani S.; Tragni E.; Catapano A.; Sala A.

Glutathione peroxidase activity and blood lipids in women with diabetes mellitus and myocardial infarction
pp. 61-61(1)
Authors: Dzhekova-Stojkova S.; Krstevska M.; Bosilkova G.; Ivanovski V.

Superoxide dismutase and glutathione peroxidase activity in hypertensive women
pp. 61-62(2)
Authors: Krstevska M.; Dzhekova-Stojkova S.; Bosilkova G.; Trpchevska L.

Antioxidant enzymes in women with dyslipidemia
pp. 62-62(1)
Authors: Bosilkova G.; Dzhekova-Stojkova S.; Krstevska M.; Trpchevska L.

A new method of lipoprotein analysis using agarose gel electrophoresis and differential staining of lipids
pp. 62-62(1)
Authors: Kido T.; Kurata H.; Matsumoto A.; Tobiyama R.; Kamiyama M.; Utsunomiya K.; Tajima S.; Itakura H.; Kondo K.

The relation between fractional removal rate of fat emulsion (K2) and postheparin plasma lipoprotein lipase
pp. 62-62(1)
Authors: Sakuma N.; Ikeuchi R.; Kimura G.

Pseudohypertriglycerydemia in 3-year-old boy
pp. 62-62(1)
Authors: Kubalska J.; Szaplyko J.; Adamowicz M.; Kuryl T.; Moszczynska A.; Casselius E.; Gradowska W.; Taybert J.; Chmielik J.; Pronicka E.

Enhance of chylomicron-like emulsion lipolysis in patients with heart failure
pp. 62-63(2)
Authors: Vinagre C.G.; Sposito A.C.; Stolf N.; Bocchi E.; Amancio R.F.; Ramires J.A.F.; Maranhao R.C.

Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis
pp. 63-63(1)
Authors: Miyashita Y.; Hitsumoto T.; Ohsawa H.; Uchi T.; Noike H.; Kanai M.; Yoshinuma M.; Murano T.; Watanabe H.; Shirai K.

Platelet volume and coronary heart disease
pp. 63-63(1)
Authors: Holgado C.; Aznar A.; de la Vega J.M.; Holgado T.; Rico M.A.

Atherosclerosis in children and youth. A morphometric multinational investigation of WHO/ISFC (1986-96) using atherometric system
pp. 63-63(1)
Authors: Fernandez-Britto J.E.; Wong R.; Contreras D.; Nordet P.; Sternby N.

Rapid development of vein graft atheroma in apoe-deficient mice: Implication for gene transfer study
pp. 63-63(1)
Authors: Hu Y.; Dietrich H.; Zou Y.; Huemer U.; Li C.; Mayr M.; Xu Q.

Ramipril induces regression of the atherosclerotic lesions in apo E deficient mice
pp. 64-64(1)
Authors: Hayek T.; Raz A.; Coleman R.; Heinrich R.; Kaplan M.

Fatty streak development in marmoset aorta depends on both high fat/cholesterol diet and endothelial injury
pp. 64-64(1)
Authors: Mano M.; Head R.J.; Abbey M.

Application of a rabbit ear chamber to continuous intravital-microscopic study on atherogenesis in vivo
pp. 64-64(1)
Authors: Asano M.; Ohkubo C.

Effect of atorvastatin treatment on structure and ultrastructure in the aorta of dyslipidemic rabbits
pp. 64-64(1)
Authors: Aragoncillo P.; Navarro-Cid J.; de las Heras N.; Vazquez-Perez S.; Cediel E.; Sanz-Rosa D.; Diaz C.; Hernandez G.; Lahera V.; Cachofeiro V.

Development of a lipid-rich, unstable plaque in rabbits, monitored by histology and intravascular ultrasound
pp. 64-65(2)
Authors: Chiesa G.; Di Mario C.; Vignati L.; Marchesi M.; Monteggia E.; Laucello M.; Lorusso V.; Franceschini G.; Newton R.; Sirtori C.R.

Treatment of endogenous hypercholesterolemic rabbits with CI-1027, a novel lipid regulator, results in significantly increased HDL-C and decreased LDL-C
pp. 65-65(1)
Authors: Auerbach B.J.; Dash D.; Bousley D.; Davila-Delgado E.; Essenburg A.; Krause B.R.

The ACAT inhibitor, avasimibe, reduces aortic cholesterol content in apoE knockout mice, independent of its plasma hypocholesterolemic effects
pp. 65-65(1)
Authors: Auerbach B.J.; Dash D.; Bousley D.; Essenburg A.; Davila-Delgado E.; Bocan T.; Homan R.; Kraus B.R.

The new thromboxane receptor antagonist, S18886, but not aspirin inhibits atherogenesis in apo E deficient mice
pp. 65-65(1)
Authors: Cayatte A.J.; Du Y.; Oliver-Krasinski J.; Lavielle G.; Verbeuren T.J.; Cohen R.A.

Effect of genetic background and diet on plasma fibrinogen in mice. Possible relation with susceptibility for atherosclerosis
pp. 65-65(1)
Authors: Rezaee F.; Maas A.; Verheijen J.H.; Koopman J.

Expression of human apolipoprotein (apo) A-II in apoE deficient mice reproduces the effects of a major familial combined hyperlipidemia gene
pp. 66-66(1)
Authors: Escola-Gil J.C.; Julve-Gil; Marzal-Casacuberta A.; Ordonez-Llanos J.; Gonzalez-Sastre F.; Blanco-Vaca F.

Long term vitamin E feeding attenuates aortic atherosclerosis independent of plasma lipid levels in heterozygous LDL-receptor deficient mice
pp. 66-66(1)
Authors: Volger O.L.; van der Boom J.; van Duyvenvoorde W.; van Wijk K.; Mathot J.; Leenen R.; Roodenburg A.J.C.; Havekes L.M.; Princen H.M.G.

Altered expression of multiple genes in the aorta of apolipoprotein-E deficient mice with atherosclerosis: Determination by hybridization of arrayed cDNA clones
pp. 66-66(1)
Authors: Geng Y.-J.; Kil K.; Casscells S.W.; Willerson J.T.

Paradoxical increase of plaque growth and collagen deposition in atherosclerotic mice lacking plasminogen activator inhibitor-1 (PAI-1)
pp. 66-66(1)
Authors: Luttun A.; Herbert J.-M.; Moons L.; Tipping P.; Collen D.; Lupu F.; Carmeliet P.

Leptin and cardiovascular risk factors among overweight diabetics
pp. 67-67(1)
Authors: Koeva L.; Dimitrov D.; Rousseva T.

Clinical trial of plantstanol-ester induced cholesterol-lowering in NIDDM-patients
pp. 67-67(1)
Authors: van der Vleuten P.; Bouter K.

Characteristics of diabetic patients with early coronary disease
pp. 67-67(1)
Authors: Batalla A.; Cubero G.I.; Reguero J.J.R.; Hevia S.; Merino E.; Bustillo E.; Cortina A.

Prevalence of non insulin dependent diabetes millitus during 1976-1997 in Iran
pp. 67-67(1)
Authors: Sajady F.; SarrafZadegan N.; Alikhasih H.; Mohammadifard N.; Abdar N.

Preventative effect of 'PROBUCOL' on micro-albuminuria in type II diabetic patients
pp. 67-67(1)
Authors: Amano K.; Kasuga M.

Relevance of genetic predisposition and lifestyle factors in the pathogenesis of type 2 diabetes mellitus and cardiovascular complications
pp. 68-68(1)
Authors: Kruijshoop M.; Blaak E.E.; Feskens E.J.M.; van Dam R.; Dekker J.M.; Heine R.J.; de Bruin T.W.A.; Jansen H.; Molhuizen H.; Nijpels G.; Stehouwer C.; steering group project

Apolipoprotein (a) phenotype and retinopathy in diabetic patients
pp. 68-68(1)
Authors: Suzuki T.; Okazaki K.; Sato S.; Nakano H.; Ohba K.; Metori S.

Urinary excretion of N-acetyl--D-glucosaminidase is related to diabetic macroangiopathy in elderly type 2 diabetes mellitus
pp. 68-68(1)
Authors: Oba K.; Okazaki K.; Sato S.; Suzuki T.; Nakano H.; Metori S.

Plasma triglyceride levels decrease in NIDDM subjects when consuming high fat, low carbohydrate intakes
pp. 68-68(1)
Authors: Jumpsen J.; Ryan E.A.; French M.A.; Goh Y.K.; Clandinin M.T.

Preheparin lipoprotein lipase mass might be reflecting the amount of produced lipoprotein lipase in the whole body
pp. 68-68(1)
Authors: Koide K.; Oyama T.; Murano T.; Watanabe H.; Miyashita Y.; Totuka M.; Shirai K.

Postprandial increase in atherogenic remnant-lipoprotein in type 2 diabetes mellitus with fasting normolipidemia
pp. 69-69(1)
Authors: Takayanagi N.; Onuma T.; Kato S.; Abe K.; Nomiyama T.; Ogihara T.; Shimizu T.; Tanaka Y.; Usuki Y.; Kawamori R.

7-ketocholesterol-induced apoptosis of vascular smooth muscle cells enhanced under diabetic condition
pp. 69-69(1)
Authors: Miyashita Y.; Oyama T.; Totsuka M.; Watanabe H.; Shirai K.

Structural and antioxidant properties of serum albumin altered by glycation and oxidation
pp. 69-69(1)
Authors: Bourdon E.; Loreau N.; Blache D.

Lipid lowering therapy is advisable in more than half type 2 diabetic patients in fairly good metabolic control
pp. 69-69(1)
Authors: Torri A.; Branchi A.; Berra C.; Dalla Valle E.; Sommariva D.

Plasmin generation reduced in hypertriglyceridemia, but enhanced in low HDL cholesterolemia
pp. 69-70(2)
Authors: Kawaguchi A.; Kato H.; Yamamoto A.

Relationship between hemostasis and hyperhomocysteinemia induced by methionine loading in vitamin B₆ and folate deficiency
pp. 70-70(1)
Authors: Chang S.-J.; Liao C.Y.; Li Y.-C.

Increased prevalence of haemostatic abnormalities and osteoarthritis (OA) in a young cohort of patients with coronary heart disease (CHD) and hyperlipidemia
pp. 70-70(1)
Authors: Colquhoun D.M.; Cheras P.A.; Nielsen G.V.L.; Dubois P.; Outerbridge H.K.; Battistutta D.

Thrombogenetic risk factors in patients with thrombangitis obliterans
pp. 70-70(1)
Authors: Brodmann M.; Renner W.; Stark G.; Winkler M.; Pabst E.; Hofmann C.; Koppel H.; Pilger E.

Effects of atorvastatin on fibrinolytic system in patients with familial hypercholesterolemia
pp. 70-70(1)
Authors: Pucci L.; Bandinelli S.; Lucchesi D.; Caricato F.; Navalesi R.; Bertolotto A.; Penno G.

Multimodal imaging of human atherosclerosis and its complications
pp. 71-71(1)
Author: Ansari A.

Ischemic heart disease and cerebrovascular disorders in patients with high HDL blood level and with low HDL, normal cholesterol and triglycerides
pp. 71-71(1)
Author: Lipovetsky B.

Evaluation of aortic atherosclerosis by transesophageal echocardiography
pp. 71-71(1)
Authors: Fazendas P.; Cotrim C.; Oliveira L.M.; Carrageta M.

Age-related changes in lipid composition of platelets' membranes as a risk factor of development and progression of atherosclerosis in elderly people
pp. 71-71(1)
Authors: Korkushko O.V.; Sarkisov K.G.; Lishnevskaya V.Y.; Gorbach T.I.

Elevated homocysteine levels in patients qualified for coronary bypass surgery
pp. 71-72(2)
Authors: Bukowska H.; Brykczynski M.; Wiechowski S.; Chelstowski K.; Naruszewicz M.

Chlamydia pneumoniae and cytomegalovirus-positive immune complexes and acute phase proteins in stroke
pp. 72-72(1)
Authors: Gromadzka G.; Tarnacka B.; Czlonkowska A.

Severe multivessel coronary disease in young patients with HIV infection following protease inhibitors therapy
pp. 72-72(1)
Authors: Cea-Calvo L.; Munoz-Delgado G.; Diaz-Simon R.; Hernandez F.; Sopena J.; Pozuelo A.; Gonzalez-Gomez C.

Growth factor influence on the vascular wall neoangiogenesis
pp. 72-72(1)
Author: Mikadze I.

Homocysteine stimulates monocyte chemotaxis towards endothelial cells
pp. 72-72(1)
Authors: Sung F.; Siow Y.; O K.

Soluble intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in dyslipidemic patients
pp. 72-73(2)
Authors: Nowicka G.; Jarosz A.; Kozlowska-Wojciechowska M.

Polymorphisms at the promoter region of the CTLA-4 gene are associated with Wegener's granulomatosis in a Swedish population
pp. 73-73(1)
Authors: Giscombe R.; Wang X.; Lefvert A.K.

Production of specific antibodies to the long platelet derived growth factor (PDGF) AA isoform
pp. 73-73(1)
Authors: Ostergren-Lunden G.; Lustig F.; Fager G.; Olivas R.G.; Hoebeke J.

Urokinase plasminogen activator in injured adventitia increases the number of myofibroblasts and augments neoadventitia growth
pp. 73-73(1)
Authors: Plekhanova O.; Parfyonova Y.; Stepanova V.; Bobik A.; Tkachuk V.

Efficacy and safety of a new HMG-CoA reductase inhibitor, NK-104, in patients with hypertriglyceridemia - Randomized double-blind, cross-over placebo controlled study
pp. 73-73(1)
Authors: Sasaki J.; Ikeda Y.; Yamamoto K.; Ageta M.; Arakawa K.

Risk evaluation and stroke prevention in the elderly - Cerivastatin trial (RESPECT)
pp. 73-74(2)
Authors: Lauterbach K.W.; Binnen T.; Harnischmacher U.; Ludwig D.; Hanrath P.; Krone W.; Lehmacher W.; Leys D.; Neuhaus K.-L.; Windler E.

Efficacy and safety of cerivastatin 0.8 mg versus pravastatin 40 mg for treatment of dyslipidaemia
pp. 74-74(1)
Authors: Rubinstein A.; Marais A.D.; Szostak W.B.; Colquhoun D.; Keber I.; Werba J.P.; Bertolami M.; Stolero D.; Tal S.

Clinical evaluations of pleiotropic effects of pravastatin
pp. 74-74(1)
Authors: Yamashita T.; Nakamura H.; Miyajima E.; Homma M.; Tada N.; Satoh N.

Use of simvastatin treatment in patients with combined hyperlipidemia in clinical practice
pp. 74-74(1)
Authors: Vicari R.; Wan G.; Aura A.; Alexander C.; Markson L.; Teutsch S.; Simvastatin Combined Hyperlipidemia Registry Group

Lipid lowering treatment in early coronary disease
pp. 74-74(1)
Authors: Batalla A.; Cubero G.I.; Reguero J.J.R.; Hevia S.; Merino E.; Sanmartin J.C.; Sieres M.; Cortina A.

Fluvastatin extended-release formulation is effective in treating primary hypercholesterolaemia
pp. 74-75(2)
Authors: Insull W.; Marais A.D.; Aronson R.; Manfreda S.

Atorvastatin and short courses of plasmapheresis in the treatment of patients with homozygouse familial hypercholesterolaemia
pp. 75-75(1)
Authors: Sussekov A.; Kotova L.; Eliseev A.; Tvorogova M.; Kukharchuk V.

Atorvastatin for severe treatment refractory hypercholesterolemia
pp. 75-75(1)
Authors: Heller F.; Descamps O.; Boland B.

Global coronary heart disease risk changes under combined drug treatment of metabolic syndrome patients
pp. 75-75(1)
Authors: Perova N.; Mamedov M.; Kosmatova O.; Metelskaya V.

Low dose pravastatin therapy alters endothelium generated mediators and thrombotic tendency
pp. 75-76(2)
Authors: Tokgozoglu L.; Koylan N.; Soydan I.; Domanic N.; Enar R.; Atalar E.; Kay&unknown;kcioglu M.

An improved HPLC method for endogenous methylated arginine derivatives
pp. 76-76(1)
Authors: Laakso J.; Paiva H.; Lehtimaki T.; Helle T.; Vesalainen R.; Knuuti J.; Laaksonen R.

Effect of hypolipidemic treatment (atorvastatin or bezafibrate) on chitotriosidase levels in mixed dyslipidemia. The ATOMIX study
pp. 76-76(1)
Authors: Canudas J.; Cenarro A.; Civeira F.; Aristegui R.; Diaz C.; Sol J.M.; Hernandez G.; Pocovi M.; ATOMIX Study Group

Replacement of usual lipid lowering treatment by atorvastatin: Effect on plasma lipid levels
pp. 76-76(1)
Authors: Bowden J.F.; Pritchard P.H.; Frohlich J.J.

Lipid lowering with pravastatin in acute unstable angina: Effect on heart rate variability
pp. 76-76(1)
Authors: Vaulin N.A.; Yavelov I.S.; Averkov O.V.; Gratsiansky N.A.

Comparison of the efficacy and safety of atorvastatin and fenofibrate in the treatment of mixed hyperlipidemia
pp. 76-77(2)
Authors: Tunca M.; Comlekci A.; Akar S.; Yesil S.

Spontaneous myocardial infarction of WHHL rabbits
pp. 77-77(1)
Authors: Shiomi M.; Ito T.

Effects of lectins on calcification by vesicles isolated from aortas of cholesterol-fed rabbits
pp. 77-77(1)
Authors: Hsu H.H.T.; Tawfik O.; Sun F.

Rabbit strain affects patterns of aortic permeability and lipid deposition
pp. 77-77(1)
Authors: Staughton T.; Barnes S.; Weinberg P.

Increased production of very low density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II: A mouse model of familial combined hyperlipidemia
pp. 77-77(1)
Authors: Julve-Gil J.; Escola-Gil J.C.; Marzal-Casacuberta A.; Ordonez-Llanos J.; Gonzalez-Sastre F.; Blanco-Vaca F.

Dietary vegetable-, wood- or vegetable/wood-derived stanol esters reduce atherosclerotic lesion size and severity in APOE*3-Leiden transgenic mice
pp. 77-78(2)
Authors: Volger O.L.; van der Boom J.; de Wit E.C.M.; van Duyvenvoorde W.; Hornstra G.; Plat J.; Havekes L.M.; Princen H.M.G.; Mensink R.P.

Pathogenesis of fatty acid induced atherogenic dyslipoproteinemia
pp. 79-79(1)
Author: Sniderman A.D.

Insulin resistance and postprandial lipid metabolism
pp. 79-79(1)
Author: Erkelens D.W.

Fatty acids and insulin resistance: A genetic and physiological perspective
pp. 79-79(1)
Author: Aitman T.J.

Fatty acid binding proteins in different human adipose tissue depots: Relationships to serum insulin concentrations
pp. 79-79(1)
Authors: Fisher R.M.; Eriksson P.; Hoffstedt J.; Hamsten A.; Arner P.

Changes in matrix proteoglycans induced by fatty acids in hepatic cells; effects on lipoprotein binding
pp. 79-80(2)
Authors: Olsson U.; Egnell A.-C.; Rodriguez Lee M.; Bondjers G.; Camejo G.

Adipose tissue insulin resistance in familial combined hyperlipidemia (FCH), but not type 2 diabetes mellitus (DM2)
pp. 80-80(1)
Authors: van der Kallen C.J.H.; Bouwman F.G.; van de Hulst R.W.J.; Boeckx W.D.; de Bruin T.W.A.

Spectrum of nuclear lamin A/C mutations and metabolic phenotypes in familial partial lipodystrophy
pp. 80-80(1)
Authors: Hegele R.A.; Anderson C.M.; Wang J.; Cao H.

VEGF gene transfer in the treatment of coronary heart disease and peripheral vascular disease
pp. 80-80(1)
Author: Yla-Herttuala S.

Gene therapy for dyslipidemias
pp. 80-80(1)
Author: Chan L.

Gene therapy for proliferative vascular disease
pp. 80-81(2)
Author: Walsh K.

VEGF-C adenovirus gene transfer reduces intima formation in rabbits
pp. 81-81(1)
Authors: Hiltunen M.O.; Laitinen M.; Turunen M.P.; Jeltsch M.; Hartikainen J.; Rissanen T.T.; Laukkanen J.; Niemi M.; Kossila M.; Hakkinen T.P.; Kivel a A.; Enholm B.; Mansukoski H.; Turunen A.-M.; Alitalo K.; a-Herttuala S.Y.

Feasibility of gene transfer through bone marrow cells using lentiviral vector
pp. 81-81(1)
Authors: Jovinge S.; Harpf A.; Branen L.; Shah P.K.; Rajavashisth T.

Therapeutic angiogenesis induced by HGF: Potential gene therapy for ischemic diseases
pp. 81-81(1)
Authors: Aoki M.; Morishita R.; Taniyama Y.; Yamasaki K.; Kaneda Y.; Ogihara T.

Optimisation of in vivo arterial transfection
pp. 81-81(1)
Authors: O'Brien E.; Ma X.; Glover C.; Miller H.

CHD risk factors in indians: A global comparison
pp. 82-82(1)
Author: Reddy K.S.

Globalisation and coronary heart disease
pp. 82-82(1)
Author: Beaglehole R.

Males with mild and severe coronary atherosclerosis in five european populations over a 25 year period
pp. 82-82(1)
Authors: Sternby N.H.; Zhdanov V.S.; Vikhert A.M.; Duskova J.

The second nation-wide study of atherosclerosis in infants, children and young adults in Japan
pp. 82-82(1)
Authors: Yutani C.; Japanese Pathological Study Group of Atherosclerosis in Youth

A pathologic survey of atherosclerotic lesions in chinese youth
pp. 82-83(2)
Authors: Zhao H.-L.; Li H.-F.; You L.-B.; Critchley J.A.J.H.

Hypercholesterolaemia as a risk factor for coronary heart disease in the Asia-Pacific region: The ASPAC study
pp. 83-83(1)
Authors: Keech A.; Zambahari R.; Ritchie G.; Thongtang V.; White H.; Carruthers A.; Kalim H.; Asia-Pacific CHD Risk Factor Collaborative Group

Renal transplantation arteriosclerosis is a cell-mediated intimal immune response
pp. 83-83(1)
Authors: Zhao H.-L.; Li H.-F.; You L.-B.; Critchley J.A.J.H.

Expression of thrombospondin-1 (TSP-1) in human cardiac allografts
pp. 83-83(1)
Authors: Zhao X.M.; Hu Y.; Michell R.; Miller G.; Libby P.

Transplant vascular disease: Potential sites of intervention
pp. 83-83(1)
Author: Hayry P.

Endothelial cell' changes in microvessels of organ allografts
pp. 83-84(2)
Authors: Jurukova Z.; Knieriem H.J.; Minkova V.

Lipoprotein(a) inhibits proliferation of human umbilical venous endothelial cells (HUVEC) in vitro
pp. 84-84(1)
Authors: Wahn F.; Michalk D.; Querfeld U.

The role of vascular smooth muscle cell apoptosis in atherosclerosis and restenosis
pp. 84-84(1)
Author: Bennett M.R.

Inhibition of angioplasty restenosis by vascular brachytherapy: Mechanisms of action and role of the adventitia
pp. 84-84(1)
Author: Wilcox J.N.

Construction and characterization of an HBGAM/FGF-1 chimera for vascular tissue engineering
pp. 84-84(1)
Authors: Xue L.; Woloson S.; Hampton B.; Burgess W.; Greisler H.

Relationship between monocyte chemoattractant protein-1 and restenosis after coronary angioplasty
pp. 85-85(1)
Authors: Cipollone F.; Marini M.; Fazia M.; Torello M.; Paloscia L.; Materazzo G.; D'Annunzio E.; Chiarelli F.; Cuccurullo F.; Mezzetti A.

A novel model for restenosis in the carotid arteries of APOE-/- and LDLR-/- mice
pp. 85-85(1)
Authors: von der Thusen J.H.; van Berkel T.J.C.; Biessen E.A.L.

Polylysine as a vehicle for extracellular matrix-targeted intravascular drug delivery, providing high accumulation and long-term retention within the vessel wall
pp. 85-85(1)
Authors: Sakharov D.V.; Emeis J.J.; Rijken D.C.

A locus conferring resistance to diet-induced hypercholesterolemia and atherosclerosis on mouse chromosome 2
pp. 85-85(1)
Authors: Lusis A.J.; Mouzeyan A.; Choi J.; Allayee H.; Wang X.; Sinsheimer J.; Phan J.; Castellani L.W.; Reue K.; Davis R.C.

PPARS: Fatty acid-activated receptors controlling lipid metabolism and inflammation
pp. 86-86(1)
Author: Staels B.

Obesity and diabetes gene loci in genetically obese mice
pp. 86-86(1)
Authors: Attie A.D.; Stoehr J.; Nadler S.; Rabaglia M.; Yandell B.; Schueler K.; Metz S.

Consumption of plant stanol esters increase LDL receptor expression in mononuclear cells from non-hypercholesterolemic subjects
pp. 86-86(1)
Authors: Plat J.; Mensink R.P.

Role of sequestration in hepatic uptake of chylomicron remnants
pp. 86-86(1)
Authors: Yu K.C.-W.; Chen W.; Cooper A.D.

Possible role of SREBP1c in fish oil-mediated regulation of APOC-III gene expression
pp. 86-87(2)
Authors: Dallongeville J.; Raspe E.; Bauge E.; Fruchart J.C.; Staels B.

Long-chain N-3 fatty acids improve large artery elasticity in humans; DHA and EPA are equivalent
pp. 87-87(1)
Authors: Nestel P.; Shige H.; Pomeroy S.; Cehun M.; Raederstorff D.

Proteoglycans in atherosclerosis and restenosis
pp. 87-87(1)
Author: Wight T.N.

Expression of ''proteoglycan-binding defective LDL'' in transgenic mice
pp. 87-87(1)
Author: Boren J.

Secretory sphingomyelinase and atherosclerosis
pp. 87-87(1)
Authors: Tabas I.; Marathe S.; Kuriakose G.; Williams K.J.; Tribble D.

Molecular basis for the association of group IIA phospholipase A₂ and decorin in atherosclerotic lesions
pp. 87-88(2)
Authors: Sartipy P.; Johansen B.; Gasvik K.; Hurt-Camejo E.

Binding of C-reactive protein (CRP) to native and modified low density lipoprotein (LDL) particles
pp. 88-88(1)
Authors: Taskinen S.; Kovanen P.T.; Jarva H.; Meri S.; Pentikainen M.O.

PD166793, a matrix metalloproteinase inhibitor, blunts the progression of atherosclerosis in rabbits in the absence of plasma cholesterol lowering
pp. 88-88(1)
Authors: Bocan T.; Bak-Mueller S.; Rosebury W.; Hallak H.; O'Brien P.; Dagle C.; Robertson A.; Lu X.; Major T.

Oxidized LDL binds to macrophage-secreted extracellular matrix and is taken up by macrophages: An alternative approach to studies on lipoprotein cellular uptake
pp. 88-88(1)
Authors: Kaplan M.; Aviram M.

Pathology of vulnerable plaques
pp. 88-89(2)
Author: Falk E.

Is there a mouse model of plaque rupture?
pp. 89-89(1)
Author: Jackson C.L.

Visualization of the vulnerable plaque
pp. 89-89(1)
Author: Pasterkamp G.

Increased serum MMP-9 concentrations in patients with angiographically assessed coronary artery disease
pp. 89-89(1)
Authors: Kalela A.; Koivu T.A.; Kanervisto J.; Sillanaukee P.; Lehtimaki T.; Nikkari S.T.

Lipoprotein-associated Phospholipase A2 (Lp PLA₂), an inflammatory marker and novel independent risk factor in the West of Scotland Coronary Prevention Study (WOSCOPS)
pp. 89-89(1)
Authors: Packard C.J.; O'Reilly D.; Caslake M.J.; McIntosh G.; Macphee C.H.; Suckling K.E.; Krishna M.; Rumley A.; Lowe G.; WOSCOPS Group

Genomic searches for genes that influence risk factors for CVD
pp. 89-90(2)
Author: Hixson J.E.

Genetic factors and the response of CVD risk factors to regular exercise
pp. 90-90(1)
Author: Bouchard C.

Gene environment interaction in determining risk of ischaemic heart disease
pp. 90-90(1)
Authors: Humphries S.E.; Talmud P.J.; Cooper J.; Waterworth D.M.; Day I.N.M.; Miller G.J.

Linkage of blood pressure to a locus on chromosome 4 in dutch dyslipidemic famiilies
pp. 90-90(1)
Authors: Allayee H.; de Bruin T.W.A.; Cantor R.M.; Aouizerat B.E.; Lusis A.J.; Rotter J.I.

A quantitative trait locus for vascular cellular adhesion molecule-1 levels on chromosome 19
pp. 90-90(1)
Authors: Mahaney M.C.; Almasy L.; Comuzzie A.G.; Cole S.A.; Hixson J.E.; MacCluer J.W.; Stern M.P.; Blangero J.

Acute coronary event risk-increasing polymorphisms of _2B adrenergic receptor and serum paraoxonase genes. demonstration of a gene-gene instruction
pp. 90-91(2)
Authors: Tuomainen T.-P.; Lakka T.A.; Snapir A.; Malin R.; Lehtimaki T.; Koulu M.; Scheinin M.; Salonen J.T.

A poymorphism of the Cholesteryl Ester Transfer Protein (CETP) gene predicts Cardiovascular (CV) events in the West of Scotland Coronary Prevention Study (WOSCOPS)
pp. 91-91(1)
Authors: Freeman D.J.; Wilson V.; McMahon A.D.; Packard C.J.; Gaffney D.

Cholesterol absorption: Mechanisms and inhibitors
pp. 91-91(1)
Authors: Wright S.D.; Hernandez M.; Patel S.; Steinger M.; Kim D.; Montenegro J.; Lisnock J.; Sparrow C.; Detmers P.A.; Chao Y.S.

HDL modifying agents: From small molecules to recombinant proteins for intervention in vascular disease
pp. 91-91(1)
Author: Newton R.S.

HDL mutants and mimetics for the direct treatment of vascular disease
pp. 91-91(1)
Author: Sirtori C.R.

Bay 13-9952 (implitapide), an inhibitor of the Microsomal Triglyceride Transfer Protein (MTP), blocks secretion of Apo-B-lipoproteins
pp. 91-92(2)
Authors: Gruetzmann R.; Beuck M.; Mueller U.; Nielsch U.

Probucol increases hepatic expression of High Density Lipoprotein (HDL) receptor, scavenger receptor class B type I (SR-BI), in vitro and in vivo. - enhancement of reverse cholesterol transport (RCT)
pp. 92-92(1)
Authors: Tsujii K.; Hirano K.; Matsuura F.; Nakagawa-Toyama Y.; Sugimoto T.; Matsuyama A.; Matsumoto K.; Yamashita S.; Matsuzawa Y.

Rapid normalization of pre-established hypercholesterolemia in rhesus monkeys by the potent cholesterol absorption inhibitor ezetimibe (SCH58235)
pp. 92-92(1)
Authors: Compton D.S.; Davis H.R.; van Heek M.

The effect of metoprolol CR/XL on atherosclerosis
pp. 92-92(1)
Authors: Bondjers G.; Wiklund O.; Hulthe J.; Schmidt C.; Olofsson S.O.; Wikstrand J.

Graft endothelialization by in vitro lining
pp. 93-93(1)
Authors: Deutsch M.; Meinhart J.; Zilla P.

Strategies for engineering endothelialization of blood contacting devices
pp. 93-93(1)
Author: Greisler H.

Total tissue engineered vascular grafts
pp. 93-93(1)
Author: Niklason L.E.

Gene transfer approaches to restenosis
pp. 93-93(1)
Authors: Levy R.; Klugherz B.; Wilensky R.

Prevention of atherosclerosis: Do we practice what we know?
pp. 93-94(2)
Author: De Backer G.

Shared care programs. Do they improve patient compliance?
pp. 94-94(1)
Authors: de Velasco J.; Rodriguez J.A.; Ridocci F.

Quality assurance of secondary prevention of coronary artery disease
pp. 94-94(1)
Author: Israelsson B.

Why can't we do a better job? A systems approach to improving preventive cardiology services
pp. 94-94(1)
Author: Pearson T.A.

Proatherogenic potentials of genetic deficiency of a major receptor for oxidized LDL, CD36. - A possible candidate gene responsible for multiple risk factor clustering syndrome with insulin resistance
pp. 95-95(1)
Authors: Kuwasako T.; Hirano K.; Nozaki S.; Tomiyama Y.; Yamashita S.; Matsuzawa Y.

Effect of atorvastatin on apolipoprotein B-100 kinetics in visceral obesity
pp. 95-95(1)
Authors: Chan D.; Barrett P.H.R.; Mori T.A.; Beilin L.J.; Redgrave T.G.; Watts G.F.

Chylomicron remnant metabolism in obese men with and without hypertriglyceridaemia
pp. 95-95(1)
Authors: Chan D.; Watts G.F.; Barrett P.H.R.; Mamo J.; Mori T.A.; Martins I.; Redgrave T.G.

Chylomicron remnant metabolism studied with a new stable isotope breath test in centrally obese subjects
pp. 95-96(2)
Authors: Watts G.F.; Barrett P.H.R.; Chan D.; Stuckey B.; Martins I.; Redgrave T.G.

Insulin action in young healthy adult offspring of parents with type 2 diabetes: Effect of vitamin E in a randomised double-blind placebo-controlled trial
pp. 96-96(1)
Authors: McSorley P.; Bell P.; Young I.; Atkinson A.; Ennis C.; Sheridan B.; Fee J.; McCance D.

Insulin peptides and common carotid artery intima media thickness in 58-year old men
pp. 96-96(1)
Authors: Bokemark L.; Fagerberg B.; Wikstrand J.

Interaction of serum apolipoproteins with scavenger receptor (SR)-BI
pp. 96-96(1)
Authors: Thuahnai S.T.; Lund-Katz S.; Phillips M.C.

LDL-particle size and insulin resistance, measured with the hyperinsulinemic clamp technique
pp. 96-96(1)
Authors: Hulthe J.; Bokemark L.; Wikstrand J.; Wiklund O.; Fagerberg B.

Plasma acylation stimulating protein and C3 in FCHL families
pp. 96-97(2)
Authors: Ylitalo K.; Pajukanta P.; Nuotio I.; Meri S.; Taskinen M.-R.

Using bioinformatics to identify novel SNPs in genes with relevance for insulin resistance
pp. 97-97(1)
Authors: Bennet A.M.; Naslund T.; Morgenstern R.; de Faire U.

Obesity overrules the beneficial gender efects on triglyceride metabolism in non-obese subjects
pp. 97-97(1)
Authors: Halkes C.J.M.; Castro Cabezas M.; v. Wijk J.P.H.; Erkelens D.W.

Altered LDL-subfraction profile in individuals with normal glucose tolerance and insulin resistance
pp. 97-97(1)
Authors: Winkler K.; Jacob S.; Bachmann O.P.; Rett K.; Dahl D.B.; Marz W.; Haring H.U.

Triglyceride and VLDL-triglyceride responses to carbohydrate or fat is different in non-diabetic obese and lean women
pp. 97-97(1)
Authors: Dallongeville J.; Lebel P.; Velly C.; Fruchart J.C.; Romon M.

Effects of exercise-training and Gemfibrozil on HDL concentration and composition in abdominally obese men
pp. 98-98(1)
Authors: Pascot A.; Despres J.P.; Bergeron J.; Dumont M.; Brochu M.; Lemieux I.; Almeras N.; Lamarche B.; Prud'homme D.

Is the high triglyceride-low HDL cholesterol atherogenic dyslipidemia a small, dense LDL or HDL phenotype?
pp. 98-98(1)
Authors: Lemieux I.; Pascot A.; Dumont M.; Brochu M.; Almeras N.; Bergeron J.; Lamarche B.; Prud'homme D.; Despres J.P.

Abdominal obesity: The critical correlate of elevated plasma C-reactive protein levels associated with the features of the insulin resistance syndrome in men
pp. 98-98(1)
Authors: Despres J.P.; Pascot A.; Bergeron J.; Lemieux I.; Dumont M.; Almeras N.; Nadeau A.; Prud'homme D.

Conjugated linoleic acid (CLA) reduced abdominal visceral fat in obese men with the metabolic syndrome
pp. 98-98(1)
Authors: Riserus U.; Berglund L.; Vessby B.

The impact of dietary intervention on lipid metabolism and the development of insulin resistance in mice
pp. 98-99(2)
Authors: Muurling M.; Dahlmans V.E.H.; Jong M.C.; Mensink R.P.; Havekes L.M.

Hyperglycemia, increased insulin sensitivity and decreased adiposity in human APOC1 transgenic mice
pp. 99-99(1)
Authors: Jong M.; Dahlmans V.; Muurling M.; Koopmans S.-J.; Pijl H.; Romijn H.; Havekes L.

Influence of fenofibrate on apo B metabolism in familial combined hyperlipidaemia
pp. 99-99(1)
Authors: Caslake M.J.; Lahdenpera S.; Perttunen-Nio H.; Bedford D.; Packard C.J.; Taskinen M.-R.

Insulin resistance in the St. Thomas' Mixed Hyperlipidaemic (SMHL) rabbit, a model for familial combined hyperlipidaemia
pp. 99-99(1)
Authors: de Roos B.; Caslake M.J.; Ardern H.A.; Benson G.M.; Suckling K.E.; Packard C.J.

Plasma polyunsaturated fatty acid and threonine allele in codon 54 of the fatty acid binding protein 2 gene in obese Japanese children
pp. 99-99(1)
Authors: Okada T.; Uchida N.; Iwata F.; Hara M.; Noto N.; Harada K.; Hattori H.; Egashira T.

Mechanisms of hepatic VLDL-apoB overproduction in an insulin resistant hamster model
pp. 99-100(2)
Authors: Taghibiglou C.; Carpentier A.; Van-Iderstine S.; Chen B.; Lewis G.F.; Adeli K.

The SstI polymorphism at the apolipoprotein C-III gene locus predict insulin sensitivity in healthy subjects
pp. 100-100(1)
Authors: Perez-Jimenez F.; Lopez-Miranda J.; Velasco M.J.; Pinillos D.; Castro P.; Martinez P.P.; Gomez P.; Marin C.; Bravo D.; Ordovas J.M.; Mayer J.

Impact of body mass index on the expression of hypertriglyceridemia in familial lipoprotein lipase (LPL) deficiency is related to the type of LPL gene mutation
pp. 100-100(1)
Authors: Julien P.; Bergeron J.; Gaudet D.; Cadelis F.; Perron P.

The effect of combined therapy of atenolol with simvastatin and with fenofibrat on the insulin resistance syndrome
pp. 100-100(1)
Authors: Mamedov M.N.; Kosmatova O.V.; Perova N.V.; Oganov R.G.

Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase
pp. 100-100(1)
Authors: Hikita M.; Kobayashi J.; Bujo H.; Takahashi K.; Otabe M.; Morisaki N.; Saito Y.

Effects of eicosapentaenoic acid (EPA) and bezafibrate (BEZA) on serum lipids and blood pressure in insulin resistance
pp. 101-101(1)
Authors: Masai M.; Fujioka Y.; Tsuboi S.; Okumura T.; Morimoto S.; Fujiwara M.; Iwasaki T.

Determination of reference values for fasting insuline levels in a representative sample of the adult Quebec population
pp. 101-101(1)
Authors: Scarsella C.; Almeras N.; Mauriege P.; Blanchet C.; Dewailly E.; Despres J.P.; Bergeron J.

Influence of etofibrate therapy on the insulinemia in the IVGTT in subjects with the polymetabolic syndrome depending on ace gene polymorphism
pp. 101-101(1)
Authors: Klimek K.; Ciechanowicz A.; Morawiec-Borowiak D.; Wesolowska T.; Dutkiewicz G.; Szmatloch E.; Naruszewicz M.

Association of visceral fat with coronary risk factors in population-based postmenopausal women
pp. 101-101(1)
Authors: Hernandez-Ono A.; Monter-Carreola G.; Zamora-Gonzalez J.; Cardoso-Saldana G.; Posadas-Sanchez R.; Torres-Tamayo M.; Posadas-Romero C.

The preproendothelin-1 promoter as a tool for specific gene therapy to angiogenic vascular endothelial cells
pp. 101-102(2)
Authors: Varda-Bloom N.; Shaish A.; Gonen A.; Levkovitz H.; Harats D.

Periadventitial lacZ gene transfer to pig carotid arteries using a biodegradable collagen collar or a wrap of collagen sheet with adenoviruses and plasmid-liposome complexes
pp. 102-102(1)
Authors: Pakkanen T.M.; Laitinen M.; Hippelainen M.; Hiltunen M.O.; Alhava E.; Yla-Herttuala S.

PDGF-receptor- antisense gene transfer decreases proliferation and PDGF binding of human primary smooth muscle cells
pp. 102-102(1)
Authors: Turunen A.-M.; Krettek A.; Lustig F.; Bondjers G.; Yla-Herttuala S.

Adventitial ex vivo gene transfer to rabbit carotid artery using autologous vascular smooth muscle cells
pp. 102-102(1)
Authors: Turunen M.P.; Hiltunen M.O.; Lehtolainen P.; Koponen J.; Pimenoff V.; Turunen A.-M.; Yla-Herttuala S.

Adenovirus-mediated extracellular superoxide dismutase gene transfer in vitro and in vivo
pp. 102-102(1)
Authors: Turunen P.; Laukkanen M.O.; Leppanen P.; Yla-Herttuala S.

Sterol regulation of human LDL receptor expression in gene therapy
pp. 102-103(2)
Authors: Heeren J.; Schnieders F.; Beisiegel U.

Extracorporeal fibrinogen-adsorption - A new procedure to improve plasma and whole blood viscosity
pp. 103-103(1)
Authors: Richter W.O.; Schneidewind J.M.; Ramlow W.; Koll R.; Klinkmann H.

Hepatic levels of TNF-, but not of IL-2 and IFN- correlate with DNA turnover and hepatoxicity after adenoviral apo A-I transfer
pp. 103-103(1)
Authors: Van Linthout S.; Collen D.; De Geest B.

Sustained expression of human apo A-I in 3 different mouse strains
pp. 103-103(1)
Authors: De Geest B.; Van Linthout S.; Collen D.

Simvastatin, HDL cholesterol and the regression to the mean. A reappraisal
pp. 103-103(1)
Authors: Branchi A.; Fiorenza A.M.; Torri A.; Muzio F.; Rovellini A.; Sommariva D.

Risk factors for coronary atherosclerosis in men and women: Epidemiological study based on pathological assessment
pp. 104-104(1)
Authors: Nakashima Y.; Iwamoto H.; Chen Y.X.; Kiyohara Y.; Fujishima M.; Sueishi K.

Hyperhomocysteinemia in patients with ischaemic heart disease and mediterranean dietary pattern
pp. 104-104(1)
Authors: Vrentzos G.; Ganotakis E.; Zacharis E.; Delaveraki E.; Vardakis K.; Papadakis J.; Gravanis A.; Emmanouel D.

Frequency distribution of apoB and CETP polymorphism, plasma lipids and coronary heart disease in Taiwanese population
pp. 104-104(1)
Authors: Wu J.; Lee Y.T.; Hsu H.C.

Insulin resistance syndrome and obesty in the Circassian population in Israel
pp. 104-104(1)
Authors: Haron Y.; Hussein O.; Linn S.

Is pulse pressure a predictor for the incidence of stroke in men? The Korea Medical Insurance Corporation Study
pp. 104-105(2)
Authors: Suh I.; Jee S.H.; Nam C.M.; Kim I.S.; Appel L.J.

Apolipoprotein E concentration and polymorphism in relation with triglycerides in six European countries: The ApoEurope Project
pp. 105-105(1)
Authors: Siest G.; Schiele F.; De Bacquer D.; Vincent-Viry M.; Beisiegel U.; Ehnholm C.; Evans A.; Kafatos A.; Martins M.C.; Sans S.; Sass C.; De Backer G.; Visvikis S.

Cause of early stroke fatality in Poland
pp. 105-105(1)
Authors: Mendel T.; Baroni I.; Lechowicz W.; Ryglewicz D.; Czlonkowska A.

Epidemiology of high density lipoprotein levels in pre- and post-menopause: The Brisighella Heart Study
pp. 105-105(1)
Authors: Reggiani A.; Cicero A.F.G.; Martini C.; Odoo F.O.; Dormi A.; Gaddi A.

Association between lipidic phenotype variability and CHD/CVD in a large rural population: The Brisighella Study
pp. 105-106(2)
Authors: Cicero A.F.G.; Martini C.; Nativio V.; Reggiani A.; Dormi A.; Gaddi A.

Low incidence of xanthomas in heterozygous familial hypercholesterolemia (FH) in Spain
pp. 106-106(1)
Authors: Garces C.; Artalejo F.R.; Serrano A.; Bonillo J.G.; Almagro F.; Garrido J.A.; Zuniga M.; de Oya M.

Peripheral vascular surgery in women - Trends and outcome changes in the Stockholm area (Sweden)
pp. 106-106(1)
Authors: Hultgren R.; Olofsson P.; Wahlberg E.

Dramatic increase of premature myocardial infarction in Isfahan, Iran
pp. 106-106(1)
Authors: Sayed-Tabatabaei F.A.; Sarraf-Zadegan N.; Boshtam M.; Hoseini S.

Coronary atherosclerosis in subjects 60-69 years old in three European cities and its changes over a 25 year period
pp. 106-106(1)
Authors: Zhdanov V.S.; Sternby N.H.; Vikhert A.M.

Appropriate treatment of dyslipidaemia in angiographically defined British Columbians
pp. 106-107(2)
Authors: Francis M.; Frohlich J.

The impact of landmark clinical trials on secondary prevention of acute myocardial infarction (AMI) in Spain. Prevese 98 study
pp. 107-107(1)
Authors: de Oya M.; Lopez-Sendon J.L.; de Teresa E.; Velasco-Rami J.; Villa E.; Cosin J.; PREVESE 98 Study Group

Relationship of absolute risk of atherosclerosis to hyperhomocysteinemia in Slovak males after myocardial infarction
pp. 107-107(1)
Authors: Lietava J.; Dukat A.; Kotrec M.; Krpciar V.; Krizanova D.; Vohnout B.; Caprnda M.; Strelinger J.; Blazicek P.; Robblee P.; Fodor G.

Beneficial effects of combined treatment statins-antioxidant agents in patients with multiple coronary risk factors - Epidemiological study
pp. 107-107(1)
Authors: Lazar A.; Salajan A.; Gilau L.; Burta O.; Salajan V.; Lazar L.; Lazar O.

Mouse model of transplant arteriosclerosis: Role of ICAM-1
pp. 107-107(1)
Authors: Hu Y.; Dietrich H.; Zou Y.; Wick G.; Xu Q.

Inhibitory effect of TS-962, an acat inhibitor, on intimal thickening of carotid artery in a rabbit balloon injury model
pp. 108-108(1)
Authors: Tomoike H.; Asami Y.; Yamagishi I.; Akiyoshi K.; Fukushima K.

Genetic risk factors in coronary heart disease (CHD) and restenosis
pp. 108-108(1)
Authors: Previato L.; Sandrelli F.; Stefanato S.; Codemo A.; Razzolini R.; Cortella I.; Martini S.; Gabelli C.; Crepaldi G.

Nitrated tyrosine in porcine stented and unstented vein grafts
pp. 108-108(1)
Authors: Gadsdon P.; Yim A.; Wan S.; Newby A.C.; Angelini G.D.; Jeremy J.Y.

Elevated C-reactive protein (CRP) after percutaneous transluminal coronary angioplasty (PTCA) is a predictor of restenosis
pp. 108-108(1)
Authors: Morimoto S.; Fujioka Y.; Tsuboi S.; Okumura T.; Masai M.; Tateishi J.; Masutani M.; Iwasaki T.

Homocysteine, copper and caeruloplasmin in patients undergoing coronary artery bypass graft surgery
pp. 108-109(2)
Authors: Jeremy J.Y.; Lotto A.; Day A.; Shukla N.; Ascione R.; Wan I.; Stansbie D.; Angelini G.D.

The proliferation profile and histology of symptomatic coronary in-stent restenosis lesions
pp. 109-109(1)
Authors: O'Brien E.; Glover C.; Ma X.; Labinaz M.; Veinot J.

BO-653, a novel antioxidant suppressed VSMC proliferation and neointimal thickening in rabbit and porcine models
pp. 109-109(1)
Authors: Nakamura M.; Sato T.; Kaise H.; Kim M.J.; Sekimori R.; Kawabe Y.; Yamaguchi H.; Miyauchi K.; Schwarz R.S.; Kodama T.; Cynshi O.

Green tea catechins beneficially modify cholesterol metabolism in the hypercholesterolaemic rabbit
pp. 109-109(1)
Authors: Bursill C.A.; Abbey M.; Roach P.D.

Dietary trans fatty acids lower HDL cholesterol and impair endothelial function
pp. 109-109(1)
Authors: de Roos N.M.; Bots M.L.; Katan M.B.

Dietary trans fatty acids adversely affect the composition of postprandial lipoproteins
pp. 110-110(1)
Authors: Samman S.; Gatto L.M.; Sullivan D.R.

Adipose tissue trans fatty acid levels and first myocardial infarction
pp. 110-110(1)
Authors: Clifton P.M.; Noakes M.

Genistein, a bioactive component found in soybeans, enhances relaxation to porcine coronary artery, in vitro
pp. 110-110(1)
Authors: Lee M.Y.K.; Man R.Y.K.

Green tea and epigallocatechin gallate modulate cholesterol homeostasis in HepG2 cells
pp. 110-110(1)
Authors: Bursill C.A.; Roach P.D.

Eicosapentaenoic acid and docosahexaenoic acid have differential effects on serum lipids and lipoproteins, LDL-particle size, glucose & insulin, in dyslipidaemic men
pp. 110-111(2)
Authors: Mori T.A.; Burke V.; Puddey I.B.; Watts G.F.; O'Neal D.N.; Best J.D.; Beilin L.J.

Response of small, dense low density lipoprotein (LDL) to fish-oil is influenced by apo E genotype
pp. 111-111(1)
Authors: Minihane A.M.; Talmud P.; Wright J.; Murphy M.; Williams C.; Griffin B.

Pomegranate juice consumption reduces oxidative stress and low density lipoprotein atherogenic modifications: studies in the atherosclerotic apolipoprotein E deficient mice and in humans
pp. 111-111(1)
Authors: Fuhrman B.; Volkova N.; Dornfeld L.; Rosenblat M.; Kaplan M.; Hayek T.; Presser D.; Aviram M.

Effect of a standardized grape seed extract on LDL-susceptibility to oxidation in smoking men
pp. 111-111(1)
Authors: Vigna G.B.; Costantini F.; Zanca R.; Santoro G.; Tangerini A.; Schena F.; Aldini G.; Bombardelli E.; Morazzoni P.; Mezzetti A.; Fellin R.

Effect of mercury, iron and antioxidants on atherosclerosis in LDLR-deficient mice
pp. 111-111(1)
Authors: Leppanen P.; Seppanen K.; Salonen J.T.; Yla-Herttuala S.

Cholesterol increases DNA methylation in rabbit tissues
pp. 111-112(2)
Authors: Westerlund S.; Laukkanen M.O.; Alakuijala P.; Turunen P.; Yla-Herttuala S.

Effects of combination of tall oil sterols and n-3 fatty acids on atherosclerotic lesion development in cholesterol-fed (0.2% w/w) apo E-KO mice
pp. 112-112(1)
Authors: Lukic T.; Novak E.; Moghadasian M.H.; Frohlich J.; Pritchard H.

A novel linoleic acid derivative shows a marked inhibition of platelet aggregation
pp. 112-112(1)
Authors: Minullina I.; Ibragimov O.

Decrease in plasma LDL-C and apolipoprotein-B by sitostanol-ester in Japanese
pp. 112-112(1)
Authors: Homma Y.; Ishikawa T.; Tateno M.; Mitaniyama A.

Light to moderate alcohol intake and the metabolic syndrome in 60-year old men and women
pp. 112-112(1)
Authors: Rosell M.; Hellenius M.-L.; de Faire U.

Dietary monounsaturated fatty acids and carbohydrates increase VLDL-cholesterol and atherosclerosis in mice via an apo E dependent pathway
pp. 113-113(1)
Authors: Merkel M.; Carasco W.V.; Hudgins L.C.; Breslow J.L.

Inhibition of low-density lipoprotein oxidation by fish protein and antioxidants
pp. 113-113(1)
Authors: Kondo K.; Iwamoto T.; Hosoda K.; Kamiyama M.; Hirano R.; Kidou T.; Matsumoto A.; Watanabe S.; Itakura H.

Red wine polyphenolic compounds preserve normal arterial relaxation by preventing -tocopherol consumption, cholesterol oxidation, and endothelium dysfunction
pp. 113-113(1)
Authors: Deckert V.; Athias A.; Desrumaux C.; Palleau V.; Gambert P.; Masson D.; Lagrost L.

Exploring new functions of polyunsaturated fatty acids on the gene expression using DNA chip
pp. 113-113(1)
Authors: Matsumoto A.; Fujiwara Y.; Hanaka S.; Itakura H.; Ishii M.; Tsutsumi S.; Aburatani H.

Effect of an oleic acid-rich diet on postprandial apolipoproteins in type 2 diabetes
pp. 113-114(2)
Authors: Owens D.; Madigan C.; Ryan M.; Collins P.; Johnson A.; Tomkin G.H.

Macrophage-mediated oxidation of LDL may be counteracted by phenolic compounds contained in extra-virgin olive oil
pp. 114-114(1)
Authors: Masella R.; Vari R.; Scazzocchio B.; Di Benedetto R.; De Vincenzi M.; Giovannini C.

Influence of Apo A4 genotypes (Apo4-347 mutation) on the lipid response to diet in familial hypercholesterolemia
pp. 114-114(1)
Authors: Carmena-Ramon R.; Real J.T.; Civera M.; Ascaso J.F.; Ordovas J.M.; Carmena R.

Tocotrienols from rice bran oil have no effects on levels of LDL cholesterol and markers for cholesterol synthesis and absorption
pp. 114-114(1)
Authors: Kerckhoffs D.A.J.M.; Mensink R.P.; de Bruin T.W.A.; Trautwein E.A.; Brouns F.; Hornstra G.

Effect of dietary fatty acid modification on blood lipids, lipoproteins and lipoprotein subclasses in men
pp. 114-114(1)
Authors: Tholstrup T.; Sandstrom B.; Petersen M.; Hoy C.-E.; Marckmann P.